David Findlay

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

David Findlay is Professor of Orthopaedic Research in the Discipline of Orthopaedics and Trauma at The University of Adelaide. His undergraduate and postgraduate studies were at The University of Melbourne, followed by postdoctoral work at the National Institutes of Health, Maryland, USA. He has worked in bone and joint research for over 30 years, focusing on the mechanisms of pathological bone loss, both systemic, such as in osteoporosis, or focal, such as in bone cancer or around orthopaedic implants.

Career
Publications
Supervision
Contact

Appointments

Date Position Institution name

1996 - ongoing Professor of Orthopaedic Research University of Adelaide

Date	Position	Institution name
1996 - ongoing	Professor of Orthopaedic Research	University of Adelaide

Education

Date	Institution name	Country	Title
1979 - 1982	University of Melbourne	Australia	PhD
1974 - 1977	University of Melbourne	Australia	MSc
1970 - 1972	University of Melbourne	Australia	BSc

Postgraduate Training

Date Title Institution Country

1985 - 1987 Post-doctoral training National Institutes of Health (NIH) United States
Research Interests

Cell Biology Orthopaedics

Date	Title	Institution	Country
1985 - 1987	Post-doctoral training	National Institutes of Health (NIH)	United States

Journals

Year	Citation
2024	Muratovic, D., Atkins, G. J., & Findlay, D. M. (2024). Is RANKL a potential molecular target in osteoarthritis?. Osteoarthritis and Cartilage, 32(5), 493-500. DOI Scopus5 Europe PMC2
2023	Muratovic, D., Findlay, D. M., Quinn, M. J., Quarrington, R. D., Solomon, L. B., & Atkins, G. J. (2023). Microstructural and cellular characterisation of the subchondral trabecular bone in human knee and hip osteoarthritis using synchrotron tomography. Osteoarthritis and Cartilage, 31(9), 1224-1233. DOI Scopus4 WoS1
2022	Ormsby, R. T., Hosaka, K., Evdokiou, A., Odysseos, A., Findlay, D. M., Solomon, L. B., & Atkins, G. J. (2022). The Effects of Vitamin E Analogues α-Tocopherol and γ-Tocotrienol on the Human Osteocyte Response to Ultra-High Molecular Weight Polyethylene Wear Particles. Prosthesis, 4(3), 480-489. DOI Scopus2 WoS1
2022	Dorraki, M., Muratovic, D., Fouladzadeh, A., Verjans, J. W., Allison, A., Findlay, D. M., & Abbott, D. (2022). Hip osteoarthritis: A novel network analysis of subchondral trabecular bone structures. PNAS Nexus, 1(5), pgac258-1-pgac258-11. DOI Scopus1
2022	Muratovic, D., Findlay, D. M., Quarrington, R. D., Cao, X., Solomon, L. B., Atkins, G. J., & Kuliwaba, J. S. (2022). Elevated levels of active Transforming Growth Factor β1 in the subchondral bone relate spatially to cartilage loss and impaired bone quality in human knee osteoarthritis. Osteoarthritis and Cartilage, 30(6), 896-907. DOI Scopus8 WoS1 Europe PMC2
2022	Hofstaetter, J. G., Atkins, G. J., Kato, H., Kogawa, M., Blouin, S., Misof, B. M., . . . Ito, N. (2022). A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 Gene. Calcified Tissue International, 111(4), 430-444. DOI Scopus2 WoS1 Europe PMC2
2021	Lee, Y. -R., Findlay, D. M., Muratovic, D., & Kuliwaba, J. S. (2021). Greater heterogeneity of the bone mineralisation density distribution and low bone matrix mineralisation characterise tibial subchondral bone marrow lesions in knee osteoarthritis patients. Bone, 149, 1-10. DOI Scopus9 WoS4 Europe PMC4
2020	Lee, Y., Findlay, D., Muratovic, D., Gill, T., & Kuliwaba, J. (2020). Raman microspectroscopy demonstrates reduced mineralization of subchondral bone marrow lesions in knee osteoarthritis patients. Bone Reports, 12, 100269-1-100269-9. DOI Scopus6 WoS4 Europe PMC2
2019	Muratovic, D., Findlay, D. M., Cicuttini, F. M., Wluka, A. E., Lee, Y. R., Edwards, S., & Kuliwaba, J. S. (2019). Bone marrow lesions in knee osteoarthritis: regional differences in tibial subchondral bone microstructure and their association with cartilage degeneration. Osteoarthritis and Cartilage, 27(11), 1653-1662. DOI Scopus35 WoS20 Europe PMC20
2019	Ormsby, R. T., Solomon, L. B., Stamenkov, R., Findlay, D. M., & Atkins, G. J. (2019). Evidence for gender-specific bone loss mechanisms in periprosthetic osteolysis. Journal of Clinical Medicine, 9(1), 1-15. DOI Scopus6 WoS5 Europe PMC2
2019	Ormsby, R. T., Solomon, L. B., Yang, D., Crotti, T. N., Haynes, D. R., Findlay, D. M., & Atkins, G. J. (2019). Osteocytes respond to particles of clinically-relevant conventional and cross-linked polyethylene and metal alloys by up-regulation of resorptive and inflammatory pathways. Acta Biomaterialia, 87, 296-306. DOI Scopus41 WoS32 Europe PMC22
2019	Zhu, S., Zhu, J., Zhen, G., Hu, Y., An, S., Li, Y., . . . Cao, X. (2019). Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. Journal of Clinical Investigation, 129(3), 1076-1093. DOI Scopus267 WoS174 Europe PMC195
2018	Alliston, T., Hernandez, C. J., Findlay, D. M., Felson, D. T., & Kennedy, O. D. (2018). Bone marrow lesions in osteoarthritis: what lies beneath. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 36(7), 1818-1825. DOI Scopus61 WoS44 Europe PMC37
2018	Muratovic, D., Findlay, D., Cicuttini, F., Wluka, A., Lee, Y. -R., & Kuliwaba, J. (2018). Bone matrix microdamage and vascular changes characterize bone marrow lesions in the subchondral bone of knee osteoarthritis. Bone, 108, 193-201. DOI Scopus51 WoS35 Europe PMC25
2018	Yang, D., Wijenayaka, A., Solomon, L., Pederson, S., Findlay, D., Kidd, S., & Atkins, G. (2018). Novel insights into Staphylococcus aureus deep bone infections: the involvement of osteocytes. mBio, 9(2), e00415-18-1-e00415-18-10. DOI Scopus124 WoS92 Europe PMC76
2018	Yang, D., Anderson, P., Wijenayaka, A., Barratt, K., Triliana, R., Stapledon, C., . . . Atkins, G. (2018). Both ligand and VDR expression levels critically determine the effect of 1α,25-dihydroxyvitamin-D₃ on osteoblast differentiation. Journal of Steroid Biochemistry and Molecular Biology, 177, 83-90. DOI Scopus14 WoS10 Europe PMC8
2018	Kogawa, M., Khalid, K., Wijenayaka, A., Ormsby, R., Evdokiou, A., Anderson, P., . . . Atkins, G. (2018). Recombinant sclerostin antagonises effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size. American Journal of Physiology - Cell Physiology, 314(1), 53-61. DOI Scopus25 WoS20 Europe PMC15
2017	Daish, C., Blanchard, R., Gulati, K., Losic, D., Findlay, D., Harvie, D., & Pivonka, P. (2017). Estimation of anisotropic permeability in trabecular bone based on microCT imaging and pore-scale fluid dynamics simulations. Bone Reports, 6, 129-139. DOI Scopus28 Europe PMC11
2017	Thewlis, D., Fraysse, F., Callary, S., Verghese, V., Jones, C., Findlay, D., . . . Solomon, L. (2017). Postoperative weight bearing and patient reported outcomes at one year following tibial plateau fractures. Injury, 48(7), 1650-1656. DOI Scopus28 WoS17 Europe PMC14
2017	Liapis, V., Zysk, A., DeNichilo, M., Zinonos, I., Hay, S., Panagopoulos, V., . . . Evdokiou, A. (2017). Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Medicine, 6(9), 2164-2176. DOI Scopus8 WoS7 Europe PMC5
2017	Clark, J., & Findlay, D. (2017). Musculoskeletal health in the context of spinal cord injury. Current Osteoporosis Reports, 15(5), 433-442. DOI Scopus18 WoS14 Europe PMC9
2017	Panagopoulos, V., Liapis, V., Zinonos, I., Hay, S., Leach, D. A., Ingman, W., . . . Evdokiou, A. (2017). Peroxidase enzymes inhibit osteoclast differentiation and bone resorption. Molecular and Cellular Endocrinology, 440(C), 8-15. DOI Scopus17 WoS15 Europe PMC13
2017	Zysk, A., DeNichilo, M., Panagopoulos, V., Zinonos, I., Liapis, V., Hay, S., . . . Evdokiou, A. (2017). Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer Letters, 386, 141-150. DOI Scopus20 WoS17 Europe PMC14
2017	Gulati, K., Prideaux, M., Kogawa, M., Lima-Marques, L., Atkins, G. J., Findlay, D. M., & Losic, D. (2017). Anodized 3D-printed titanium implants with dual micro- and nano-scale topography promote interaction with human osteoblasts and osteocyte-like cells. Journal of Tissue Engineering and Regenerative Medicine, 11(12), 3313-3325. DOI Scopus86 WoS70 Europe PMC23
2016	Findlay, D., & Kuliwaba, J. (2016). Bone-cartilage crosstalk: a conversation for understanding osteoarthritis. Bone Research, 4(1), 1-12. DOI Scopus196 WoS182 Europe PMC109
2016	Saad, S., Dharmapatni, A., Crotti, T., Cantley, M., Algate, K., Findlay, D., . . . Haynes, D. (2016). Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss. Acta Biomaterialia, 30, 311-318. DOI Scopus20 WoS14 Europe PMC13
2016	DeNichilo, M., Shoubridge, A., Panagopoulos, V., Liapis, V., Zysk, A., Zinonos, I., . . . Evdokiou, A. (2016). Peroxidase enzymes regulate collagen biosynthesis and matrix mineralization by cultured human osteoblasts. Calcified Tissue International, 98(3), 294-305. DOI Scopus12 WoS11 Europe PMC9
2016	Wijenayaka, A., Prideaux, M., Yang, D., Morris, H., Findlay, D., Anderson, P., & Atkins, G. (2016). Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D₃. Journal of Steroid Biochemistry and Molecular Biology, 164, 369-373. DOI Scopus13 WoS9 Europe PMC10
2016	Liapis, V., Zinonos, I., Labrinidis, A., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2016). Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Medicine, 5(3), 534-545. DOI Scopus25 WoS21 Europe PMC20
2016	Gulati, K., Maher, S., Chandrasekaran, S., Findlay, D., & Losic, D. (2016). Conversion of titania (TiO2) into conductive titanium (Ti) nanotube arrays for combined drug-delivery and electrical stimulation therapy. Journal of Materials Chemistry B, 4(3), 371-375. DOI Scopus41 WoS30 Europe PMC5
2016	Ormsby, R., Cantley, M., Kogawa, M., Solomon, L., Haynes, D., Findlay, D., & Atkins, G. (2016). Evidence that osteocyte perilacunar remodelling contributes to polyethylene wear particle induced osteolysis. Acta Biomaterialia, 33, 242-251. DOI Scopus60 WoS46 Europe PMC29
2016	Muratovic, D., Cicuttini, F., Wluka, A., Findlay, D., Wang, Y., Otto, S., . . . Kuliwaba, J. (2016). Bone marrow lesions detected by specific combination of MRI sequences are associated with severity of osteochondral degeneration. Arthritis Research and Therapy, 18(1), 54-1-54-11. DOI Scopus52 WoS43 Europe PMC30
2016	Prideaux, M., Findlay, D., & Atkins, G. (2016). Osteocytes: the master cells in bone remodelling. Current Opinion in Pharmacology, 28, 24-30. DOI Scopus156 WoS128 Europe PMC94
2016	Briggs, M., Kuliwaba, J., Muratovic, D., Everest-Dass, A., Packer, N., Findlay, D., & Hoffmann, P. (2016). MALDI mass spectrometry imaging of N-glycans on tibial cartilage and subchondral bone proteins in knee osteoarthritis. Proteomics, 16(11-12), 1736-1741. DOI Scopus42 WoS37 Europe PMC24
2016	Gulati, K., Johnson, L., Karunagaran, R., Findlay, D., & Losic, D. (2016). In situ transformation of chitosan films into microtubular structures on the surface of nanoengineered titanium implants. Biomacromolecules, 17(4), 1261-1271. DOI Scopus19 WoS14 Europe PMC3
2016	Prideaux, M., Schutz, C., Wijenayaka, A. R., Findlay, D. M., Campbell, D. G., Solomon, L. B., & Atkins, G. J. (2016). Isolation of osteocytes from human trabecular bone. Bone, 88, 64-72. DOI Scopus34 WoS28 Europe PMC17
2016	Gulati, K., Maher, S., Findlay, D., & Losic, D. (2016). Titania nanotubes for orchestrating osteogenesis at the bone-implant interface. Nanomedicine, 11(14), 1847-1864. DOI Scopus73 WoS57 Europe PMC30
2016	Gulati, K., Kogawa, M., Prideaux, M., Findlay, D., Atkins, G., & Losic, D. (2016). Drug-releasing nano-engineered titanium implants: therapeutic efficacy in 3D cell culture model, controlled release and stability. Materials Science and Engineering C, 69, 831-840. DOI Scopus58 WoS46 Europe PMC10
2016	Rahman, S., Gulati, K., Kogawa, M., Atkins, G., Pivonka, P., Findlay, D., & Losic, D. (2016). Drug diffusion, integration, and stability of nanoengineered drug-releasing implants in bone ex-vivo. Journal of Biomedical Materials Research Part A, 104(3), 714-725. DOI Scopus32 WoS30 Europe PMC10
2015	Wluka, A., Teichtahl, A., Maulana, R., Liu, B., Wang, Y., Giles, G., . . . Cicuttini, F. (2015). Bone marrow lesions can be subtyped into groups with different clinical outcomes using two magnetic resonance imaging (MRI) sequences. Arthritis Research and Therapy, 17(1), 270-1-270-8. DOI Scopus13 Europe PMC9
2015	Rahman, S., Ormsby, R., Santos, A., Atkins, G., Findlay, D., & Losic, D. (2015). Nanoengineered drug-releasing aluminium wire implants: comparative investigation of nanopore geometry, drug release and osteoblast cell adhesion. RSC Advances, 5(92), 75004-75014. DOI Scopus6 WoS6
2015	Ito, N., Wijenayaka, A., Prideaux, M., Kogawa, M., Ormsby, R., Evdokiou, A., . . . Atkins, G. (2015). Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Molecular and Cellular Endocrinology, 399(C), 208-218. DOI Scopus141 WoS126 Europe PMC102
2015	Wijenayaka, A., Yang, D., Prideaux, M., Ito, N., Kogawa, M., Anderson, P., . . . Atkins, G. (2015). 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. Molecular and Cellular Endocrinology, 413(C), 157-167. DOI Scopus41 WoS32 Europe PMC27
2015	Clarke, M., Russell, P., Findlay, D., Sastra, S., Anderson, P., Skinner, J., . . . Davey, R. (2015). A role for the Calcitonin respetor to limit bone loss during lactation in female mice by inhibiting osteocytic osteolysis. Endocrinology, 156(9), 3203-3214. DOI Scopus47 WoS33 Europe PMC22
2015	Gulati, K., Santos, A., Findlay, D., & Losic, D. (2015). Optimizing anodization conditions for the growth of titania nanotubes on curved surfaces. Journal of Physical Chemistry C, 119(28), 16033-16045. DOI Scopus100 WoS82
2015	Gulati, K., Kant, K., Findlay, D., & Losic, D. (2015). Periodically tailored titania nanotubes for enhanced drug loading and releasing performances. Journal of Materials Chemistry B, 3(12), 2553-2559. DOI Scopus45 WoS38 Europe PMC9
2015	Rahman, S., Atkins, G., Findlay, D., & Losic, D. (2015). Nanoengineered drug releasing aluminium wire implants: a model study for localized bone therapy. Journal of Materials Chemistry B, 3(16), 3288-3296. DOI Scopus14 WoS12 Europe PMC3
2015	Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2015). Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Letters, 357(1), 160-169. DOI Scopus40 WoS36 Europe PMC32
2014	Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., Denichilo, M., . . . Evdokiou, A. (2014). Doxorubicin overcomes resistance to drozitumab by antagonizing inhibitor of apoptosis proteins (IAPS). Anticancer Research, 34(12), 7007-7020. Scopus7 WoS4 Europe PMC5
2014	Ito, N., Peña, A., Perano, S., Atkins, G., Findlay, D., & Couper, J. (2014). First Australian report of vitamin D-dependent rickets type I. Medical Journal of Australia, 201(7), 420-421. DOI Scopus4 WoS3 Europe PMC2
2014	Prideaux, M., Wijenayaka, A., Kumarasinghe, D., Ormsby, R., Evdokiou, A., Findlay, D., & Atkins, G. (2014). SaOS2 osteosarcoma cells as an in vitro model for studying the transition of human osteoblasts to osteocytes. Calcified Tissue International, 95(2), 183-193. DOI Scopus93 WoS79 Europe PMC58
2014	Zinonos, I., Luo, K., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., . . . Evdokiou, A. (2014). Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. International Journal of Oncology, 45(2), 532-540. DOI Scopus20 WoS20 Europe PMC16
2014	Low, S., Bain, G., Findlay, D., Eng, K., & Perilli, E. (2014). External and internal bone micro-architecture in normal and Kienböck's lunates: A whole-bone micro-computed tomography study. Journal of Orthopaedic Research, 32(6), 826-833. DOI Scopus25 WoS18 Europe PMC14
2014	Findlay, D. M., & Atkins, G. J. (2014). Osteoblast-chondrocyte interactions in osteoarthritis. Current Osteoporosis Reports, 12(1), 127-134. DOI Scopus112 WoS96 Europe PMC77
2014	Stamenkov, R., Neale, S., Kane, T., Findlay, D., Taylor, D., & Howie, D. (2014). Cemented liner exchange with bone grafting halts the progression of periacetabular osteolysis. Journal of Arthroplasty, 29(4), 822-826. DOI Scopus7 WoS6 Europe PMC3
2014	Ito, N., Findlay, D., & Atkins, G. (2014). Osteocyte communication with the kidney via the production of FGF23: Remote control of phosphate homeostasis. Clinical Reviews in Bone and Mineral Metabolism, 12(1), 44-58. DOI Scopus9 WoS7
2013	Findlay, D. (2013). Long overlooked: the role of subchondral bone in osteoarthritis pathophysiology and pain. Medicographia, 35(2), 221-227.
2013	Callary, S., Thewlis, D., Rowlands, A., Findlay, D., & Solomon, L. (2013). Collecting a comprehensive evidence base to monitor fracture rehabilitation: a case study. World Journal of Orthopedics, 4(4), 259-266. DOI Scopus4 WoS4 Europe PMC2
2013	Kogawa, M., Wijenayaka, A., Ormsby, R., Thomas, G., Anderson, P., Bonewald, L., . . . Atkins, G. (2013). Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. Journal of Bone and Mineral Research, 28(12), 2436-2448. DOI Scopus135 WoS113 Europe PMC81
2013	Howie, D., Neale, S., Haynes, D., Holubowycz, O., McGee, M., Solomon, L., . . . Findlay, D. (2013). Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management. Inflammopharmacology, 21(6), 389-396. DOI Scopus39 WoS30 Europe PMC23
2013	Kogawa, M., Hisatake, K., Atkins, G., Findlay, D., Enoki, Y., Sato, T., . . . Matsumoto, M. (2013). The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-kB ligand (RANKL)-induced Osteoclast differentiation. Journal of Biological Chemistry, 288(43), 31299-31312. DOI Scopus20 WoS20 Europe PMC15
2013	Welldon, K., Findlay, D., Evdokiou, A., Ormsby, R., & Atkins, G. (2013). Calcium induces pro-anabolic effects on human primary osteoblasts associated with acquisition of mature osteocyte markers. Molecular and Cellular Endocrinology, 376(1), 85-92. DOI Scopus25 WoS24 Europe PMC19
2013	Ito, N., Findlay, D., Anderson, P., Bonewald, L., & Atkins, G. (2013). Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D₃ (1,25D) on osteocyte like cells. Journal of Steroid Biochemistry and Molecular Biology, 136(1), 183-186. DOI Scopus51 WoS42 Europe PMC38
2013	Davey, R., & Findlay, D. (2013). Calcitonin: physiology or fantasy?. Journal of Bone and Mineral Research, 28(5), 973-979. DOI Scopus70 WoS62 Europe PMC37
2013	Kogawa, M., Findlay, D., Anderson, P., & Atkins, G. (2013). Modulation of osteoclastic migration by metabolism of 25(OH)-vitamin D₃. Journal of Steroid Biochemistry and Molecular Biology, 136(1), 59-61. DOI Scopus15 WoS12 Europe PMC8
2013	Kato, N., Matsumoto, M., Kogawa, M., Atkins, G., Findlay, D., Fujikawa, T., . . . Ogata, M. (2013). Critical role of p38 MAPK for regeneration of the sciatic nerve following crush injury in vivo. Journal of Neuroinflammation, 10(1), 1-13. DOI Scopus48 WoS42 Europe PMC49
2012	Aw, M., Khalid, K., Gulati, K., Atkins, G., Pivonka, P., Findlay, D., & Losic, D. (2012). Characterization of drug-release kinetics in trabecular bone from titania nanotube implants. International Journal of Nanomedicine (online), 7, 4883-4892. DOI Scopus53 WoS44 Europe PMC15
2012	Howie, D., Neale, S., Martin, W., Costi, K., Kane, T., Stamenkov, R., & Findlay, D. (2012). Progression of periacetabular osteolytic lesions. Journal of Bone and Joint Surgery-American Volume, 94(16), 1-6. DOI Scopus23 WoS3 Europe PMC15
2012	Atkins, G., & Findlay, D. (2012). Osteocyte regulation of bone mineral: a little give and take. Osteoporosis International, 23(8), 2067-2079. DOI Scopus133 WoS108 Europe PMC83
2012	Gulati, K., Aw, M., Findlay, D., & Losic, D. (2012). Local drug delivery to the bone by drug-releasing implants: perspectives of nano-engineered titania nanotube arrays. Therapeutic Delivery, 3(7), 857-873. DOI Scopus106 WoS93 Europe PMC27
2012	Alias, E., Dharmapatni, A., Holding, C., Atkins, G., Findlay, D., Howie, D., . . . Haynes, D. (2012). Polyethylene particles stimulate expression of ITAM-related molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomaterialia, 8(8), 3104-3112. DOI Scopus20 WoS19 Europe PMC16
2012	Gulati, K., Ramakrishnan, S., Aw, M., Atkins, G., Findlay, D., & Losic, D. (2012). Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion. Acta Biomaterialia, 8(1), 449-456. DOI Scopus271 WoS230 Europe PMC79
2011	Anderson, P., Atkins, G., Turner, A., Kogawa, M., Findlay, D., & Morris, H. (2011). Vitamin D metabolism within bone cells: Effects on bone structure and strength. Molecular and Cellular Endocrinology, 347(1-2 Sp Is), 42-47. DOI Scopus52 WoS49 Europe PMC26
2011	Wijenayaka, A., Kogawa, M., Lim, H., Bonewald, L., Findlay, D., & Atkins, G. (2011). Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One, 6(10), e25900-1-e25900-9. DOI Scopus408 WoS346 Europe PMC262
2011	Howie, D., Mc Gee, M., Callary, S., Carbone, A., Stamenkov, R., Bruce, W., & Findlay, D. (2011). A preclinical study of stem subsidence and graft incorporation after femoral impaction grafting using porous hydroxyapatite as a bone graft extender. Journal of Arthroplasty, 26(7), 1050-1056. DOI Scopus6 WoS4 Europe PMC4
2011	Findlay, D., & Atkins, G. (2011). Relationship between serum RANKL and RANKL in bone. Osteoporosis International, 22(10), 2597-2602. DOI Scopus62 WoS52 Europe PMC42
2011	Dharmapatni, A., Smith, M., Crotti, T., Holding, C., Vincent, C., Weedon, H., . . . Haynes, D. (2011). TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Research & Therapy, 13(2), R51-1-R51-10. DOI Scopus36 WoS31 Europe PMC26
2011	Chehade, M., Vakaci, I., Callary, S., Findlay, D., & Solomon, L. (2011). Differentially loaded radiostereometric analysis (DLRSA) in torsion adds essential information in diaphyseal bone healing: the example of a tibial osteotomy. Journal of Bioengineering & Biomedical Sciences, 2011, 1-5. DOI
2011	Atkins, G., Haynes, D., Howie, D., & Findlay, D. (2011). Role of polyethylene particles in peri-prosthetic osteolysis: A review. World Journal of Orthopedics, 2(10), 93-101. DOI Scopus47 WoS32 Europe PMC25
2011	Atkins, G., Rowe, P., Lim, H., Welldon, K., Ormsby, R., Wijenayaka, A., . . . Findlay, D. (2011). Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. Journal of Bone and Mineral Research, 26(7), 1425-1436. DOI Scopus209 WoS185 Europe PMC148
2011	Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2011). Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. Journal of Bone and Mineral Research, 26(3), 630-643. DOI Scopus19 WoS18 Europe PMC17
2011	Turner, A., Tjahyono, F., Chiu, W., Skinner, J., Sawyer, R., Moore, A., . . . Davey, R. (2011). The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. Bone, 48(2), 354-361. DOI Scopus32 WoS30 Europe PMC17
2011	Findlay, D. M. (2011). DEBATE: IS SUBCHONDRAL BONE OR ARTICULAR CARTILAGE THE BEST TARGET FOR DMOAD DEVELOPMENT? BONE. OSTEOARTHRITIS AND CARTILAGE, 19, S4. DOI
2010	Kogawa, M., Findlay, D., Anderson, P., Ormsby, R., Vincent, C., Morris, H., & Atkins, G. (2010). Osteoclastic metabolism of 25(OH)-vitamin D-3: A potential mechanism for optimization of bone resorption. Endocrinology, 151(10), 4613-4625. DOI Scopus127 WoS101 Europe PMC72
2010	Findlay, D. (2010). If good things come from above, do bad things come from below?. Arthritis Research & Therapy, 12(3), 119-1-119-2. DOI Scopus15 WoS15 Europe PMC12
2010	Labrinidis, A., Hay, S., Liapis, V., Findlay, D., & Evdokiou, A. (2010). Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. International Journal of Cancer, 127(2), 345-354. DOI Scopus28 WoS25 Europe PMC20
2010	Kogawa, M., Anderson, P., Findlay, D., Morris, H., & Atkins, G. (2010). The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. Journal of Steroid Biochemistry and Molecular Biology, 121(1-2 Sp Iss), 277-280. DOI Scopus67 WoS52 Europe PMC29
2010	Stamenkov, R., Howie, D., Neale, S., Mc Gee, M., Taylor, D., & Findlay, D. (2010). Distribution of periacetabular osteolytic lesions varies according to component design. Journal of Arthroplasty, 25(6), 913-919. DOI Scopus6 WoS8 Europe PMC6
2009	Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Molecular Cancer Therapeutics, 8(10), 2969-2980. DOI Scopus37 WoS38 Europe PMC29
2009	Atkins, G., Welldon, K., Wijenayaka, A., Bonewald, L., & Findlay, D. (2009). Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by y-carboxylation-dependent and -independent mechanisms. American Journal of Physiology-Cell Physiology, 297(6), C1358-C1367. DOI Scopus104 WoS98 Europe PMC73
2009	Vincent, C., Findlay, D., Welldon, K., Wijenayaka, A., Zheng, T., Haynes, D., . . . Atkins, G. (2009). Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNF alpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. Journal of Bone and Mineral Research, 24(8), 1434-1449. DOI Scopus153 WoS145 Europe PMC103
2009	Atkins, G., Welldon, K., Holding, C., Haynes, D., Howie, D., & Findlay, D. (2009). The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials, 30(22), 3672-3681. DOI Scopus85 WoS80 Europe PMC68
2009	Labrinidis, A., Hay, S., Liapis, V., Ponomarev, V., Findlay, D., & Evdokiou, A. (2009). Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clinical Cancer Research, 15(10), 3451-3461. DOI Scopus65 WoS58 Europe PMC44
2009	Dharmapatni, A., Smith, M., Findlay, D., Holding, C., Evdokiou, A., Ahern, M., . . . Haynes, D. (2009). Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Research & Therapy, 11(1), R13:1-R13:11. DOI Scopus53 WoS52 Europe PMC41
2009	Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009. DOI Scopus33 WoS30 Europe PMC27
2009	Vincent, C., Kogawa, M., Findlay, D., & Atkins, G. (2009). The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. Journal of Bone and Mineral Metabolism, 27(1), 114-119. DOI Scopus56 WoS49 Europe PMC37
2009	Atkins, G., Welldon, K., Halbout, P., & Findlay, D. (2009). Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporosis International, 20(4), 653-664. DOI Scopus173 WoS151 Europe PMC108
2009	Hopwood, B., Tsykin, A., Findlay, D., & Fazzalari, N. (2009). Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone, 44(1), 87-101. DOI Scopus95 WoS85 Europe PMC65
2008	Davey, R., Turner, A., McManus, J., Chiu, W., Tjahyono, F., Moore, A., . . . Zajac, J. (2008). Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. Journal of Bone and Mineral Research, 23(8), 1182-1193. DOI Scopus89 WoS73 Europe PMC41
2008	Findlay, D., Chehade, M., Tsangari, H., Neale, S., Hay, S., Hopwood, B., . . . Fazzalari, N. (2008). Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Research & Therapy, 10(1), 1-9. DOI Scopus27 WoS24 Europe PMC18
2008	Welldon, K., Atkins, G., Howie, D., & Finlay, D. (2008). Primary human osteoblasts grow into porous tantalum and maintain an osteoblastic phenotype. Journal of Biomedical Materials Research. Part A, 84A(3), 691-701. DOI Scopus85 WoS74 Europe PMC36
2008	Labrinidis, A., Liapis, V., Thai, L., Atkins, G., Vincent, C., Hay, S., . . . Evdokiou, A. (2008). Does Apo2LTRAIL play any physiologic role in osteoclastogenesis?. Blood, 111(11), 5411-5412. DOI Scopus19 WoS15 Europe PMC8
2008	Fazzalari, N. L., Tsangari, H., Neale, S., Hay, S., Hopwood, B., Chehade, M., & Findlay, D. M. (2008). Relationship between bone RANKL MRNA levels and bone structural and turnover markers in male osteoarthritics. CALCIFIED TISSUE INTERNATIONAL, 82, S129.
2007	Atkins, G. J., Welldon, K. J., & Findlay, D. M. (2007). Strontium ranelate promotes an osteocyte-like phenotype from human primary osteoblasts ex vivo. CALCIFIED TISSUE INTERNATIONAL, 80, S71-S72.
2007	Atkins, G., Anderson, P., Findlay, D., Welldon, K., Vincent, C., Zannettino, A., . . . Morris, H. (2007). Metabolism of vitamin D₃ in human osteoblasts: Evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D₃. Bone, 40(6), 1517-1528. DOI Scopus220 WoS188 Europe PMC143
2007	Anderson, P., Atkins, G., Findlay, D., O'Loughlin, P., Welldon, K., Vincent, C., & Morris, H. (2007). RNAi-mediated silencing of CYP27B1 abolishes 1,25(OH)₂D₃ synthesis and reduces osteocalcin and CYP24 mRNA expression in human osteosarcoma (HOS) cells. Journal of Steroid Biochemistry and Molecular Biology, 103(3-5 Sp Iss), 601-605. DOI Scopus43 WoS34 Europe PMC19
2007	Tsangari, H., Findlay, D., & Fazzalari, N. (2007). Structural and remodeling indices in the cancellous bone of the proximal femur across adulthood. Bone, 40(1), 211-217. DOI Scopus26 WoS26 Europe PMC18
2007	Howie, D., Neale, S., Stamenkov, R., Mc Gee, M., Taylor, D., & Findlay, D. (2007). Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. Journal of Bone and Joint Surgery-American Volume, 89A(8), 1818-1825. DOI Scopus52 WoS46 Europe PMC34
2007	Hopwood, B., Tsykin, A., Findlay, D., & Fazzalari, N. (2007). Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-β/bone morphogenic protein signalling. Arthritis Research & Therapy, 9(5), WWW 1-WWW 21. DOI Scopus168 WoS149 Europe PMC126
2007	Findlay, D. (2007). Vascular pathology and osteoarthritis. Rheumatology, 46(12), 1763-1768. DOI Scopus228 WoS178 Europe PMC141
2006	O'Neill, S., MacLennan, A., Bass, S., Diamond, T., Ebeling, P., Findlay, D., . . . Fiatarone-Singh, M. (2006). Wytyczne postępowania z osteoporozą omenopauzalną dla lekarzy rodzinnych. Lekarz Rodzinny, 4(104), 444-455.
2006	Thai, L., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., Welldon, K., . . . Evdokiou, A. (2006). Apo21/tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Research, 66(10), 5363-5370. DOI Scopus30 WoS26 Europe PMC17
2006	Findlay, D. (2006). Regulation of cell growth mediated by the calcitonin receptor. Cellular and Molecular Biology, 52(3), 3-8. DOI Scopus8 WoS8 Europe PMC3
2006	Tsangari, H., Findlay, D., Zannettino, A., Pan, B., Kuliwaba, J., & Fazzalari, N. (2006). Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients. Bone, 39(6), 1226-1235. DOI Scopus19 WoS19 Europe PMC15
2006	Holding, C., Findlay, D., Stamenkov, R., Neale, S., Lucas, H., Dharmapatni, A., . . . Haynes, D. (2006). The correlation of RANK, RANKL and TNFα expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials, 27(30), 5212-5219. DOI Scopus112 WoS98 Europe PMC73
2006	Atkins, G., Kostakis, P., Vincent, C., Farrugia, A., Houchins, J., Findlay, D., . . . Zannettino, A. (2006). RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. Journal of Bone and Mineral Research, 21(9), 1339-1349. DOI Scopus112 WoS103 Europe PMC82
2006	Perper, S., Browning, B., Burkly, L., Weng, S., Gao, C., Giza, K., . . . Hess, H. (2006). TWEAK is a novel arthritogenic mediator. Journal of Immunology, 177(4), 2610-2620. DOI Scopus144 WoS134 Europe PMC97
2006	Butler, L., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thai, L., . . . Evdokiou, A. (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 119(4), 944-954. DOI Scopus72 WoS64 Europe PMC48
2005	Findlay, D., & Haynes, D. (2005). Mechanisms of bone loss in rheumatoid arthritis. Modern Rheumatology, 15(4), 232-240. DOI Scopus46 Europe PMC29
2005	Bouralexis, S., Findlay, D., & Evdokiou, A. (2005). Death to the bad buys: Targeting cancer via Apo2L/TRAIL. Apoptosis, 10(1), 35-51. DOI Scopus112 WoS107 Europe PMC71
2005	Zannettino, A., Holding, C., Diamond, P., Atkins, G., Kostakis, P., Farrugia, A., . . . Haynes, D. (2005). Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Journal of Cellular Physiology, 204(2), 714-723. DOI Scopus143 WoS141 Europe PMC97
2005	Atkins, G., Kostakis, P., Welldon, K., Vincent, C., Findlay, D., & Zannettino, A. (2005). Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Journal of Cellular Physiology, 203(3), 573-582. DOI Scopus30 WoS29 Europe PMC25
2005	Kuliwaba, J., Fazzalari, N., & Findlay, D. (2005). Stability of RNA isolated from human trabecular bone at post-mortem and surgery. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1740(1), 1-11. DOI Scopus36 WoS32 Europe PMC20
2005	Hopwood, B., Gronthos, S., Kuliwaba, J., Robey, P., Findlay, D., & Fazzalari, N. (2005). Identification of differentially expressed genes between osteoarthritic and normal trabecular bone from the intertrochanteric region of the proximal femur using cDNA microarray analysis. Bone, 36(4), 635-644. DOI Scopus21 WoS18 Europe PMC17
2005	Suva, L., Gaddy, D., Perrien, D., Thomas, R., & Findlay, D. (2005). Regulation of bone mass by mechanical loading: Microarchitecture and genetics. Current Osteoporosis Reports, 3(2), 46-51. DOI Scopus52 Europe PMC36
2004	O'Neill, S., MacLennan, A., Diamond, T., Ebeling, P., Findlay, D., Flicker, L., . . . Fiatarone-Singh, M. (2004). Guidelines for the management of postmenopausal osteoporosis for GPs. Australian Family Physician, 33(11), 910-919. Scopus35 Europe PMC18
2004	Findlay, D., & Sexton, P. (2004). Calcitonin. Growth Factors, 22(4), 217-224. DOI Scopus53 WoS45 Europe PMC23
2004	Crotti, T., Smith, M., Findlay, D., Zreiqat, H., Ahern, M., Weedon, H., . . . Haynes, D. (2004). Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NF[kappa]B, RANK ligand and osteoprotegerin. Biomaterials, 25(4), 565-573. DOI Scopus140 WoS124 Europe PMC103
2004	Mc Gee, M., Findlay, D., Howie, D., Carbone, A., Ward, P., Stamenkov, R., . . . Toth, C. (2004). The use of OP-1 in femoral impaction grafting in a sheep model. Journal of Orthopaedic Research, 22(5), 1008-1015. DOI Scopus53 WoS49 Europe PMC40
2004	Davey, R., MacLean, H., McManus, J., Findlay, D., & Zajac, J. (2004). Genetically modified animal models as tools for studying bone and mineral metabolism. Journal of Bone and Mineral Research, 19(6), 882-892. DOI Scopus33 WoS28 Europe PMC23
2004	Tsangari, H., Findlay, D., Kuliwaba, J., Atkins, G., & Fazzalari, N. (2004). Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone, 35(1), 334-342. DOI Scopus57 WoS54 Europe PMC39
2004	Bouralexis, S., Clayer, M., Atkins, G., Labrinidis, A., Hay, S., Graves, S., . . . Evdokiou, A. (2004). Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin. International Journal of Oncology, 24(5), 1263-1270. DOI Scopus14 WoS14 Europe PMC8
2004	Findlay, D., Welldon, K., Atkins, G., Howie, D., Zannettino, A., & Bobyn, D. (2004). The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials, 25(12), 2215-2227. DOI Scopus189 WoS161 Europe PMC72
2004	Pan, B., To, L., Farrugia, A., Findlay, D., Green, J., Gronthos, S., . . . Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone, 34(1), 112-123. DOI Scopus102 WoS91 Europe PMC68
2004	Pan, B., Farrugia, A., To, L., Findlay, D., Green, J., Lynch, K., & Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). Journal of Bone and Mineral Research, 19(1), 147-154. DOI Scopus142 WoS129 Europe PMC103
2004	Hu, Y., Zhou, H., Myers, D., Quinn, J., Atkins, G., Ly, C., . . . Ng, K. (2004). Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. Journal of Bone and Mineral Research, 19(1), 89-99. DOI Scopus44 WoS39 Europe PMC32
2003	Atkins, G., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). RANKL expression is related to the differentiation state of human osteoblasts. Journal of Bone and Mineral Research, 18(6), 1088-1098. DOI Scopus213 WoS194 Europe PMC146
2003	Stamenkov, R., Howie, D., Taylor, J., Findlay, D., Mc Gee, M., Kourlis, G., . . . Burwell, M. (2003). Measurement of bone defects adjacent to acetabular components of hip replacement. Clinical Orthopaedics and Related Research, 412(412), 117-124. DOI Scopus39 WoS30 Europe PMC12
2003	Farrugia, A., Atkins, G., To, L., Pan, B., Horvath, N., Kostakis, P., . . . Zannettino, A. (2003). Receptor activator of nuclear factor-kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Research, 63(17), 5438-5445. Scopus201 WoS185 Europe PMC138
2003	Evdokiou, A., Labrinidis, A., Bouralexis, S., Hay, S., & Findlay, D. (2003). Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone, 33(2), 216-228. DOI Scopus75 WoS70 Europe PMC49
2003	Bouralexis, S., Findlay, D., Atkins, G., Labrinidis, A., Hay, S., & Evdokiou, A. (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. British Journal of Cancer, 89(1), 206-214. DOI Scopus62 WoS59 Europe PMC36
2003	Pan, B., To, L., Farrugia, A., Kostakis, P., Atkins, G., Findlay, D., & Zannettino, A. (2003). Multiple myeloma-derived pro-inflammatory cytokines enhance osteoclastogenesis by increasing the number of RANKL-expressing STRO-1 positive osteoprogenitor cells. Blood, 102(11), 5207.
2002	Atkins, G., Bouralexis, S., Evdokiou, A., Hay, S., Labrinidis, A., Zannettino, A., . . . Findlay, D. (2002). Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone, 31(4), 448-456. DOI Scopus60 WoS60 Europe PMC38
2002	Crotti, T., Smith, M., Weedon, H., Ahern, M., Findlay, D., Kraan, M., . . . Haynes, D. (2002). Receptor activator NFκB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Annals of the Rheumatic Diseases, 61(12), 1047-1054. DOI Scopus173 WoS153 Europe PMC118
2002	Findlay, D., Raggatt, L., Bouralexis, S., Hay, S., Atkins, G., & Evdokiou, A. (2002). Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism. Journal of Endocrinology, 175(3), 715-725. DOI Scopus20 WoS14 Europe PMC10
2002	Evdokiou, A., Bouralexis, S., Atkins, G., Chai, F., Hay, S., Clayer, M., & Findlay, D. (2002). Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to APO2L/TRIAL-induced apoptosis. International Journal of Cancer, 99(4), 491-504. DOI Scopus132 WoS131 Europe PMC84
2002	O'Neill, S., Sambrook, P., Diamond, T., Ebeling, P., Ferris, L., Flicker, L., . . . Williamson, M. (2002). Guidelines for the treatment of postmenopausal osteoporosis for general practitioners. Australian Family Physician, 31(10), 921-928. Scopus9 Europe PMC3
2002	Atkins, G., Haynes, D., Zannettino, A., Capone, M., Crotti, T., & Findlay, D. (2002). Haemopoietic cells influence stromal cell gene expression during human osteoclast development. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 235.
2002	Atkins, G., Crotti, T., Loric, M., Findlay, D., Howie, D., Bain, G., & Haynes, D. (2002). Periprosthetic osteolysis is associated with wear particles stimulating factors that control osteoclast formation. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 234.
2002	Atkins, G., Crotti, T., Loric, M., Findlay, D., Smith, M., & Haynes, D. (2002). Osteolysis in bone loss pathologies is associated with similar factors that control osteoclast formation. Asia Pacific Orthopaedic Association.. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 234-235.
2002	O'Neill, S., Sambrook, P., Diamond, T., Ebeling, P., Ferris, L., Flicker, L., . . . Williamson, M. (2002). Guidelines for the treatment of postmenopausal osteoporosis for general practitioners.. Australian family physician, 31(10), 921-928. Scopus8
2001	Crotti, T. N., Smith, M. D., Weedon, H., Capone, M., Holding, C., Findlay, D. M., & Haynes, D. R. (2001). Osteoprotegerin (OPG) and RANKL expression in tissues near bone in diseases of pathological bone loss: A comparison of rheumatoid arthritis, prosthetic joint failure and periodontal disease.. JOURNAL OF BONE AND MINERAL RESEARCH, 16, S227. WoS1
2001	Kuliwaba, J. S., Findlay, D. M., Atkins, G. J., Forwood, M. R., & Fazzalari, N. L. (2001). Gene expression in human cancellous bone is similar between skeletal sites.. JOURNAL OF BONE AND MINERAL RESEARCH, 16, S327.
2001	Haynes, D., Crotti, T., Loric, M., Bain, G., Atkins, G., & Findlay, D. (2001). Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology, 40(6), 623-630. DOI Scopus188 WoS165 Europe PMC121
2001	Haynes, D., Crotti, T., Potter, A., Loric, M., Atkins, G., Howie, D., & Findlay, D. (2001). The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. Journal of Bone and Joint Surgery-British Volume, 83B(6), 902-911. DOI Scopus168 WoS137 Europe PMC102
2001	Fazzalari, N., Kuliwaba, J., Atkins, G., Forwood, M., & Findlay, D. (2001). The ratio of messenger RNA levels of receptor activator of nuclear factor kB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. Journal of Bone and Mineral Research, 16(6), 1015-1027. DOI Scopus118 WoS101 Europe PMC81
2001	Evdokiou, A., Atkins, G., Bouralexis, S., Hay, S., Raggatt, L., Cowled, P., . . . Findlay, D. (2001). Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone. International Journal of Oncology, 19(3), 625-632. DOI Scopus23 WoS22 Europe PMC15
2001	Wada, S., Yasuda, S., Nagai, T., Maeda, T., Kitahama, S., Suda, S., . . . Katayama, S. (2001). Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kB ligand and macrophage colony-stimulating factor. Endocrinology, 142(4), 1471-1478. DOI Scopus23 WoS16 Europe PMC11
2001	Atkins, G., Bouralexis, S., Haynes, D., Graves, S., Geary, S., Evdokiou, A., . . . Findlay, D. (2001). Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 28(4), 370-377. DOI Scopus86 WoS82 Europe PMC55
2001	Fazzalari, N., Kuliwaba, J., Atkins, G., Forwood, M., & Findlay, D. (2001). Osteoclast differentiation factor is dominant in controlling the extent of bone resorption. Bone, 28(5), S160. DOI
2001	Findlay, D., Bouralexis, S., Atkins, G., Chai, F., Hay, S., Clayer, M., & Evdokiou, A. (2001). Protection of normal human bone cells from Apo2L/TRAIL and chemotherapeutic drug combination-induced apoptosis. Bone, 28(5), S137. DOI
2001	Atkins, G., Evdokiou, A., Bouralexis, S., Chai, F., Hay, S., Clayer, M., & Findlay, D. (2001). Chemotherapeutic drugs sensitise osteogenic sarcoma cells but not normal human bone cells to TRAIL-mediated apoptosis. Bone, 28(5), S82.
2001	Clayer, M., Bouralexis, S., Evdokiou, A., Hay, S., Atkins, G., & Findlay, D. (2001). Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL. Journal of Orthopaedic Surgery, 9(2), 19-22. DOI Scopus18 Europe PMC10
2001	Wada, S., Yasuda, S., Nagai, T., Maeda, T., Kitahama, S., Suda, S., . . . Katayama, S. (2001). Regulation of Calcitonin Receptor by Glucocorticoid in Human Osteoclast-Like Cells Prepared in VitroUsing Receptor Activator of Nuclear Factor-κB Ligand and Macrophage Colony-Stimulating Factor.. Endocrinology, 142(4), 1471-1478. DOI
2000	Lawrence Riggs, B., Baron, R., Boyle, W. J., John Martin, T., Suda, T., Yasuda, H., . . . Zambonin-Zallone, A. M. (2000). Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. Bone, 27(6), 761-764. DOI Scopus20 Europe PMC9
2000	Atkins, G., Haynes, D., Graves, S., Evdokiou, A., Hay, S., Bouralexis, S., & Findlay, D. (2000). Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. Journal of Bone and Mineral Research, 15(4), 640-649. DOI Scopus162 WoS163 Europe PMC114
2000	Kitahama, S., Gibson, M., Hatzinikolas, G., Hay, S., Kuliwaba, J., Evdokiou, A., . . . Findlay, D. (2000). Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells. Bone, 27(1), 61-67. DOI Scopus57 WoS53 Europe PMC34
2000	Findlay, D., Atkins, G., Forwood, M., Kuliwaba, J., & Fazzalari, N. (2000). Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. Journal of Bone and Mineral Research, 15(2), 332-341. DOI Scopus46 WoS43 Europe PMC36
2000	Raggatt, L., Evdokiou, A., & Findlay, D. (2000). Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor. Journal of Endocrinology, 167(1), 93-105. DOI Scopus32 WoS25 Europe PMC11
2000	Evdokiou, A., Raggatt, L., Sakai, T., & Findlay, D. (2000). Identification of a novel calcitonin-response element in the promoter of the human p21 WAF1/CIP1 gene. Journal of Molecular Endocrinology, 25(2), 195-206. DOI Scopus12 WoS12 Europe PMC8
2000	Atkins, G., Haynes, D., Geary, S., Loric, M., Crotti, T., & Findlay, D. (2000). Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone, 26(6), 653-661. DOI Scopus69 WoS65 Europe PMC43
2000	Kuliwaba, J. S., Findlay, D. M., Atkins, G. J., Forwood, M. R., & Fazzalari, N. L. (2000). A molecular histomorphometric study of osteoarthritic cancellous bone. JOURNAL OF BONE AND MINERAL RESEARCH, 15(4), 811.
2000	Findlay, D. M., Bouralexis, S., Atkins, G. J., Hedi, L., Hay, S., & Evdokiou, A. (2000). TRAIL-induced apoptosis of osteogenic sarcoma and breast cancer cells.. JOURNAL OF BONE AND MINERAL RESEARCH, 15, S352.
1999	Atkins, G. J., Haynes, D. R., Graves, S. E., Evdokiou, A., Hay, S., Bouralexis, S., . . . Findlay, D. M. (1999). Expression of osteoclast differentiation signals by stromal elements of giant cell tumours.. JOURNAL OF BONE AND MINERAL RESEARCH, 14, S176. WoS1
1999	Raggatt, L. J., Evdokiou, A., & Findlay, D. M. (1999). Activation of the insert negative human calcitonin receptor: Phosphorylation of MAP kinase and inhibition of cellular proliferation.. JOURNAL OF BONE AND MINERAL RESEARCH, 14, S319.
1999	Kuliwaba, J. S., Findlay, D. M., Atkins, G. J., Forwood, M. R., & Fazzalari, N. L. (1999). Bone remodelling in osteoarthritic cancellous bone a molecular histomorphometric study.. JOURNAL OF BONE AND MINERAL RESEARCH, 14, S464.
1999	Sexton, P. M., Findlay, D. M., & Martin, T. J. (1999). Calcitonin. Current Medicinal Chemistry, 6(11), 1067-1093. Scopus180 WoS150 Europe PMC87
1999	Haynes, D., Atkins, G., Loric, M., Crotti, T., Geary, S., & Findlay, D. (1999). Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Bone, 25(3), 269-278. DOI Scopus40 WoS34 Europe PMC25
1999	Puche, R. C., Thomas, D. M., Udagawa, N., Hards, D. K., Quinn, J. M. W., Moseley, J. M., . . . Best, J. D. (1999). Letters to the editor (multiple letters).. Bone, 25(2).
1999	Evdokiou, A., Raggatt, L., Findlay, D., & Atkins, G. (1999). Calcitonin Receptor-Mediated Growth Suppression of HEK-293 Cells is Accompanied by Induction of p21 WAF1/CIP1 and G2/M Arrest. Molecular Endocrinology, 13(10), 1738-1750. DOI Scopus38 WoS34 Europe PMC21
1998	Thomas, D., Udagawa, N., Hards, D., Quinn, J., Moseley, J., Findlay, D., & Best, J. (1998). Insulin receptor expression in primary and cultured osteoclast-like cells. Bone, 23(3), 181-186. DOI Scopus82 Europe PMC62
1998	Celic, S., Katayama, Y., Chilco, P., Martin, T., & Findlay, D. (1998). Type 1 collagen influence on gene expression in UMR106-06 osteoblast-like cells is inhibited by genistein. Journal of Endocrinology, 158(3), 377-388. DOI Scopus31 WoS27 Europe PMC18
1998	Katayama, Y., House, C., Udagawa, N., Kazama, J., McFarland, R., Martin, T., & Findlay, D. (1998). Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts. Journal of Cellular Physiology, 176(1), 179-187. DOI Scopus51 Europe PMC40
1998	Evdokiou, A., Raggatt, L., Atkins, G. J., & Findlay, D. M. (1998). Growth inhibition by calcitonin of HEK293 cells is accompanied by induction of p21/WAF1/CIP1 and G2/M arrest. MOLECULAR BIOLOGY OF THE CELL, 9, 484A.
1997	Katayama, Y., Soulis, T., Cooper, M. E., Seeman, E., Nagata, N., Martin, T. J., & Findlay, D. M. (1997). Aminoguanidine treatment increases bone mineral density in STZ induced diabetic rats.. DIABETOLOGIA, 40, 2289.
1997	Katayama, Y., Soulis, T., Cooper, M. E., Seeman, E., Nagata, N., Martin, T. J., & Findlay, D. M. (1997). Aminoguanidine treatment increases bone mineral density in streptozotocin (STZ)-induced diabetic rats: Possible role of age formation.. JOURNAL OF BONE AND MINERAL RESEARCH, 12, S650.
1997	Suva, L. J., Flannery, M. S., Caulfield, M. P., Findlay, D. M., Jüppner, H., Goldring, S. R., . . . Chorev, M. (1997). Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor. Journal of Pharmacology and Experimental Therapeutics, 283(2), 876-884. Scopus18 Europe PMC10
1997	Gillespie, M., Thomas, R., Pu, Z. Y., Zhou, H., & Findlay, D. (1997). Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. International Journal of Cancer, 73(6), 812-815. DOI Scopus92 Europe PMC56
1997	Findlay, D., & Martin, T. (1997). Receptors of Calciotropic Hormones. Hormone and Metabolic Research, 29(3), 128-134. DOI Scopus15 Europe PMC6
1997	Findlay, D. (1997). Receptor regulation - food for thought. European Journal of Endocrinology, 137(3), 218-219. DOI
1997	Katayama, Y., Celic, S., Nagata, N., Martin, T., & Findlay, D. (1997). Nonenzymatic Glycation of Type 1 Collagen Modifies Interaction With UMR 201-10B Preosteoblastic Cells. Bone, 21(1), 237-242. DOI Scopus26 Europe PMC11
1997	Wada, S., Udagawa, N., Akatsu, T., Nagata, N., Martin, T., & Findlay, D. (1997). Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology, 138(2), 521-529. DOI Scopus49 Europe PMC24
1996	Traianedes, K., Martin, T., & Findlay, D. (1996). Regulation of osteopontin expression by type 1 collagen in preosteoblastic UMR201 cells. Connective Tissue Research, 34(1), 63-74. DOI Scopus10 Europe PMC8
1996	Ikegame, M., Rakopoulos, M., Martin, T., Moseley, J., & Findlay, D. (1996). Effects of Continuous Calcitonin Treatment on Osteoclast-like Cell Development and Clacitonin Receptor Expression in Mouse Bone Marrow Cultures. Bone and Mineral Research, 11(4), 456-465. DOI Scopus41 Europe PMC13
1996	Udagawa, N., Chan, J., Wada, S., & Findlay, D. (1996). c-fos Antisense DNA Inhibits Proliferation of Osteoclast Progenitors in Osteoclast Developments but not Macrophage Differentiation In Vitro. Bone, 18(6), 511-516. DOI Scopus17 Europe PMC11
1996	Celic, S., Chilco, P., Zajac, J., Martin, T., & Findlay, D. (1996). A Type 1 collagen substrate increases PTH/PTHrP receptor MRNA expression and suppresses PTHrP mRNA expression in UMR106-06 osteoblast -like cells. Journal of Endocrinology, 150(2), 299-308. DOI Scopus19 Europe PMC9
1996	Wada, S., Udagawa, N., Nagata, N., Martin, T., & Findlay, D. (1996). Physiological Levels of Calcitonin Regulate the Mouse Osteoclast Calcitonin Receptor by a Protein Kinase A-Mediated Mechanism. Endocrinology, 137(1), 312-320. DOI Scopus49 Europe PMC22
1996	Findlay, D., Houssami, S., Christopoulos, G., & Sexton, P. (1996). Homologous Regulation of the Rat C1a Calcitonin Receptor (CTR) in Nonosteoclastic Cells is Independent of CTR Messenger Ribonucleic Acid Changes and Cyclis Adenosine 3', 5' -Monophospate-Dependent Protein Kinase Activation. Endocrinology, 137(11), 4576-4585. DOI Scopus10 Europe PMC4
1996	Wada, S., Udagawa, N., Nagata, N., Martin, T., & Findlay, D. (1996). Calcitonin Receptor Down-Regulation Relates to Calcitonin Resistance in Mature Mouse Osteoclasts. Endocrinology, 137(3), 1042-1048. DOI Scopus43 Europe PMC19
1995	Southey, M. C., Findlay, D. M., & Kemp, B. E. (1995). Regulation of membrane-associated tyrosine phosphatases in UMR 106.06 osteoblast-like cells. Biochemical Journal, 305(2), 485-490. DOI Scopus19 Europe PMC16
1995	Findlay, D. M., Houssami, S., Sexton, P. M., Brady, C. L., Martin, T. J., & Myers, D. E. (1995). Calcium inflow in cells transfected with cloned rat and porcine calcitonin receptors. BBA - Molecular Cell Research, 1265(2-3), 213-219. DOI Scopus7 Europe PMC3
1995	Rakopoulos, M., Ikegame, M., Findlay, D. M., Martin, T. J., & Moseley, J. M. (1995). Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone, 17(5), 447-453. DOI Scopus37 Europe PMC18
1995	Manji, S. S., Zhou, H., Findlay, D. M., Martin, T. J., & Ng, K. W. (1995). Tumor necrosis factor α facilitates nuclear actions of retinoic acid to regulate expression of the alkaline phosphatase gene in preosteoblasts. Journal of Biological Chemistry, 270(15), 8958-8962. DOI Scopus13 Europe PMC10
1995	Moore, E. E., Kuestner, R. E., Stroop, S. D., Grant, F. J., Matthewes, S. L., Brady, C. L., . . . Findlay, D. M. (1995). Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Molecular Endocrinology, 9(8), 959-968. DOI Scopus105 Europe PMC49
1995	Wada, S., Martin, T. J., & Findlay, D. M. (1995). Homologous regulation of the calcitonin receptor in mouse osteoclast-like cells and human breast cancer T47D cells. Endocrinology, 136(6), 2611-2621. DOI Scopus57 Europe PMC26
1995	Ikegame, M., Rakopoulos, M., Zhou, H., Houssami, S., Martin, J. T., Moseley, J. M., & Findlay, D. M. (1995). Calcitonin receptor isoforms in mouse and rat osteoclasts. Journal of Bone and Mineral Research, 10(1), 59-65. DOI Scopus59 Europe PMC26
1995	Traianedes, K., Findlay, D. M., Martin, T. J., & Gillespie, M. T. (1995). Modulation of the signal recognition particle 54-kDa subunit (SRP54) in rat preosteoblasts by the extracellular matrix. Journal of Biological Chemistry, 270(36), 20891-20894. DOI Scopus10 Europe PMC7
1995	Houssami, S., Findlay, D. M., Brady, C. L., Martin, T. J., Epand, R. M., Moore, E. E., . . . Sexton, P. M. (1995). Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation. Molecular Pharmacology, 47(4), 798-809. Scopus51 Europe PMC21
1995	Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D. M., . . . Suda, T. (1995). Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. Journal of Experimental Medicine, 182(5), 1461-1468. DOI Scopus353 Europe PMC208
1994	Sexton, P. M., Houssami, S., Brady, C. L., Myers, D. E., & Findlay, D. M. (1994). Amylin is an agonist of the renal porcine calcitonin receptor. Endocrinology, 134(5), 2103-2107. DOI Scopus28 Europe PMC9
1994	Houssami, S., Findlay, D. M., Hilton, J. M., O'Keeffe, L. M., Martin, T. J., & Sexton, P. M. (1994). Heterogeneity in ligand recognition of calcitonin receptors. Endocrine, 2(2), 127-134. Scopus16
1994	Findlay, D. M., Houssami, S., Lin, H. Y., Myers, D. E., Brady, C. L., Darcy, P. K., . . . Sexton, P. M. (1994). Truncation of the porcine calcitonin receptor cytoplasmic tail inhibits internalization and signal transduction but increases receptor affinity. Molecular Endocrinology, 8(12), 1691-1700. DOI Scopus43 Europe PMC21
1994	Houssami, S., Findlay, D. M., Brady, C. L., Myers, D. E., Martin, T. J., & Sexton, P. M. (1994). Isoforms of the rat calcitonin receptor: Consequences for ligand binding and signal transduction. Endocrinology, 135(1), 183-190. DOI Scopus94 Europe PMC45
1994	Zhou, H., Manji, S. S., Findlay, D. M., Martin, T. J., Heath, J. K., & Ng, K. W. (1994). Novel action of retinoic acid: Stabilization of newly synthesized alkaline phosphatase transcripts. Journal of Biological Chemistry, 269(35), 22433-22439. DOI Scopus53 Europe PMC30
1994	Kuestner, R. E., Elrod, R. D., Grant, F. J., Hagen, F. S., Kuijper, J. L., Matthewes, S. L., . . . Moore, E. E. (1994). Cloning and characterization of an abundant subtype of the human calcitonin receptor. Molecular Pharmacology, 46(2), 246-255. Scopus154 Europe PMC70
1993	Ikeda, K., Michelangeli, V. P., Martin, T. J., & Findlay, D. M. (1993). Type I collagen substrate increases calcitonin and parathyroid hormone receptor‐mediated signal transduction in UMR 106–06 osteoblast‐like cells. Journal of Cellular Physiology, 156(1), 130-137. DOI Scopus27 Europe PMC17
1993	Traianedes, K., Ng, K. W., Martin, T. J., & Findlay, D. M. (1993). Cell substratum modulates responses of preosteoblasts to retinoic acid. Journal of Cellular Physiology, 157(2), 243-252. DOI Scopus32 Europe PMC18
1993	Sexton, P. M., Houssami, S., Hilton, J. M., O'Keeffe, L. M., Center, R. J., Gillespie, M. T., . . . Findlay, D. M. (1993). Identification of brain isoforms of the rat calcitonin receptor. Molecular Endocrinology, 7(6), 815-821. DOI Scopus142 Europe PMC54
1993	Zhou, H., Hammonds, R. G., Findlay, D. M., Martin, T. J., & Ng, K. W. (1993). Differential effects of transforming growth factor‐β1 and bone morphogenetic protein 4 on gene expression and differentiated function of preosteoblasts. Journal of Cellular Physiology, 155(1), 112-119. DOI Scopus55 Europe PMC33
1992	Schneider, H. G., Michelangeli, V. P., Frampton, R. J., Grogan, J. L., Ikeda, K., Martin, T. J., & Findlay, D. M. (1992). Transforming growth factor-β modulates receptor binding of calciotropic hormones and G protein-mediated adenylate cyclase responses in osteoblast-like cells. Endocrinology, 131(3), 1383-1389. DOI Scopus45 Europe PMC28
1991	McQuillan, D. J., Findlay, D. M., Hocking, A. M., Yanagishita, M., Midura, R. J., & Hascall, V. C. (1991). Proteoglycans synthesized by an osteoblast-like cell line (UMR 106-01). Biochemical Journal, 277(1), 199-206. DOI Scopus28 Europe PMC20
1991	Zhou, H., Hammonds, G. R., Findlay, D. M., Fuller, P. J., Martin, J. T., & Ng, K. W. (1991). Retinoic acid modulation of mrna levels in malignant, nontransformed, and immortalized osteoblasts. Journal of Bone and Mineral Research, 6(7), 767-777. DOI Scopus77 Europe PMC46
1991	Kurokawa, M., Michelangeli, V. P., & Findlay, D. M. (1991). Induction of calcitonin receptor expression by glucocorticoids in T47D human breast cancer cells. Journal of Endocrinology, 130(2), 321-326. DOI Scopus19 Europe PMC9
1991	Schneider, H. G., Allan, E. H., Moseley, J. M., Martin, T. J., & Findlay, D. M. (1991). Specific down-regulation of parathyroid hormone (PTH) receptors and responses to PTH by tumour necrosis factor α and retinoic acid in UMR 106-06 osteoblast-like osteosarcoma cells. Biochemical Journal, 280(2), 451-457. DOI Scopus46 Europe PMC21
1991	Sexton, P. M., Schneider, H. G., D'Santos, C. S., Mendelsohn, F. A. O., Kemp, B. E., Moseley, J. M., . . . Findlay, D. M. (1991). Reversible calcitonin binding to solubilized sheep brain binding sites. Biochemical Journal, 273(1), 179-184. DOI Scopus15 Europe PMC8
1990	Thiebaud, D., Ng, K. W., Findlay, D. M., Harker, M., & Martin, T. J. (1990). Insulinlike growth factor 1 regulates mRNA levels of osteonectin and pro‐α<inf>1</inf>(I)‐collagen in clonal preosteoblastic calvarial cells. Journal of Bone and Mineral Research, 5(7), 761-767. DOI Scopus28 Europe PMC17
1989	Ng, K. W., Manji, S. S., Young, M. F., & Findlay, D. M. (1989). Opposing Influences of Glucocorticoid and Retinoic Acid on Transcriptional Control in Preosteoblasts. Molecular Endocrinology, 3(12), 2079-2085. DOI Scopus61 Europe PMC43
1989	Findlay, D. M., Michelangeli, V. P., & Robinson, P. J. (1989). Protein kinase-c-induced down-regulation of calcitonin receptors and calcitonin-activated adenylate cyclase in T47D and BEN Cells. Endocrinology, 125(5), 2656-2663. DOI Scopus27 Europe PMC19
1989	Young, M. F., Findlay, D. M., Dominguez, P., Burbelo, P. D., McQuillan, C., Kopp, J. B., . . . Termine, J. D. (1989). Osteonectin promoter. DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells. Journal of Biological Chemistry, 264(1), 450-456. DOI Scopus54 Europe PMC33
1988	Findlay, D. M., Fisher, L. W., McQuillan, C. I., Termine, J. D., & Young, M. F. (1988). Isolation of the Osteonectin Gene: Evidence That a Variable Region of the Osteonectin Molecule Is Encoded within One Exon. Biochemistry, 27(5), 1483-1489. DOI Scopus30 Europe PMC22
1987	Moseley, J. M., Findlay, D. M., Gorman, J. J., & Martin, T. J. (1987). Photoaffinity labeling of the calcitonin receptor. Pharmacology and Therapeutics, 34(1), 51-58. DOI Scopus1 Europe PMC2
1986	Cosolo, W., Christophidis, N., Drummer, O. H., & Findlay, D. M. (1986). STUDIES ON THE CYTOTOXICITY OF PENICILLAMINE IN A RAT OSTEOGENIC SARCOMA. Clinical and Experimental Pharmacology and Physiology, 13(10), 737-743. DOI Scopus1
1986	Michelangeli, V. P., Findlay, D. M., Fletcher, A., & Martin, T. J. (1986). Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106-01). Calcified Tissue International, 39(1), 44-48. DOI Scopus44 Europe PMC27
1986	Findlay, D. M., & Martin, T. J. (1986). Kinetics of calcitonin receptor internalization in lung cancer (BEN) and osteogenic sarcoma (UMR 106–06) cells. Journal of Bone and Mineral Research, 1(3), 277-283. DOI Scopus28 Europe PMC10
1985	Findlay, D. M., Michelangeli, V. P., Martin, T. J., Orlowski, R. C., & Seyler, J. K. (1985). Conformational requirements for activity of salmon calcitonin. Endocrinology, 117(3), 801-805. DOI Scopus23 Europe PMC9
1985	Forrest, S. M., Ng, K. W., Findlay, D. M., Michelangeli, V. P., Livesey, S. A., Partridge, N. C., . . . Martin, T. J. (1985). Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin. Calcified Tissue International, 37(1), 51-56. DOI Scopus170 Europe PMC99
1984	Findlay, D. M., & Martin, T. J. (1984). Relationship between internalization and calcitonin induced receptor loss in T 47D cells. Endocrinology, 115(1), 78-83. DOI Scopus34 Europe PMC20
1983	Michelangeli, V. P., Findlay, D. M., Moseley, J. M., & Martin, T. J. (1983). Mechanisms of calcitonin induction of prolonged activation of adenylate cyclase in human cancer cells. Journal of Cyclic Nucleotide and Protein Phosphorylation Research, 9(2), 129-142. Scopus27 Europe PMC7
1983	Findlay, D. M., Michelangeli, V. P., Orlowski, R. C., & Martin, T. J. (1983). Biological activities and receptor interactions of des-leu<sup>16</sup> salmon and des-phe<sup>16</sup> human calcitonin. Endocrinology, 112(4), 1288-1291. DOI Scopus30 Europe PMC24
1983	Moseley, J. M., Findlay, D. M., Gorman, J. J., Michelangeli, V. P., & Martin, T. J. (1983). The calcitonin receptor on T 47D breast cancer cells. Evidence for glycosylation. Biochemical Journal, 212(3), 609-616. DOI Scopus16 Europe PMC12
1982	Frampton, R. J., Suva, L. J., Eisman, J. A., Findlay, D. M., Moseley, J. M., Martin, T. J., & Moore, G. E. (1982). Presence of 1,25-Dihydroxyvitamin D<inf>3</inf> Receptors in Established Human Cancer Cell Lines in Culture. Cancer Research, 42(3), 1116-1119. Scopus147 Europe PMC67
1982	Findlay, D. M., Ng, K. W., Niall, M., & Martin, T. J. (1982). Processing of calcitonin and epidermal growth factor after binding to receptors in human breast cancer cells (T 47D). Biochemical Journal, 206(2), 343-350. DOI Scopus30 Europe PMC14
1982	Moseley, J. M., Findlay, D. M., & Martin, T. J. (1982). Covalent cross-linking of a photoactive derivative of calcitonin to human breast cancer cell receptors. Journal of Biological Chemistry, 257(10), 5846-5851. DOI Scopus24 Europe PMC19
1982	Moseley, J. M., Findlay, D. M., Martin, T. J., & Gorman, J. J. (1982). A biological active photoaffinity probe used in identification of the calcitonin receptor. Clinical and Experimental Pharmacology and Physiology, 9(5).
1981	Findlay, D. M., Michelangeli, V. P., Moseley, J. M., & Martin, T. J. (1981). Calcitonin binding and degradation by two cultured human breast cancer cell lines (MCF 7 and T 47D). Biochemical Journal, 196(2), 513-520. DOI Scopus42 Europe PMC23
1981	Findlay, D. M., De Luise, M., Michelangeli, V. P., & Martin, T. J. (1981). Independent down-regulation of insulin and calcitonin receptors on a human tumour cell line. Journal of Endocrinology, 88(2), 271-281. DOI Scopus25 Europe PMC15
1981	Lamp, S. J., Findlay, D. M., & Moseley, J. M. (1981). Calcitonin responsive adenylate cyclase in human breast cancer cells. Clinical and Experimental Pharmacology and Physiology, 8(4), 397.
1981	Lamp, S. J., Findlay, D. M., Moseley, J. M., & Martin, T. J. (1981). Calcitonin induction of a persistent activated state of adenylate cyclase in human breast cancer cells (T 47D). Journal of Biological Chemistry, 256(23), 12269-12274. DOI Scopus67 Europe PMC31
1980	Martin, T. J., Findlay, D. M., MacIntyre, I., Eisman, J. A., Michelangeli, V. P., Moseley, J. M., & Partridge, N. C. (1980). Calcitonin receptors in a cloned human breast cancer cell line (MCF 7). Topics in Catalysis, 96(1), 150-156. DOI Scopus41 Europe PMC30
1980	Findlay, D. M., deLuise, M., Michelangeli, V. P., Martin, T. J., & Ellison, M. (1980). Properties of a calcitonin receptor and adenylate cyclase in ben cells, A human cancer cell line. Cancer Research, 40(4), 1311-1317. Scopus71 Europe PMC47
1980	Findlay, D. M., Micneiangell, V. P., Eisman, J. A., Framptor, R. J., Moseley, J. M., Lain, M., . . . Whitehead, R. (1980). Calcitonin and 1,25-Dihydroxyvitamin D<inf>3</inf> Receptors in Human Breast Cancer Cell Lines. Cancer Research, 40(12), 4764-4767. Scopus107 Europe PMC65
1979	Dudley, F. J., Alford, F. P., Chisholm, D. J., & Findlay, D. M. (1979). Effect of portasystemic venous shunt surgery on hyperglucagonaemia in cirrhosis: Paired studies of pre- and post-shunted subjects. Gut, 20(10), 817-824. DOI Scopus26 Europe PMC20
1979	ALFORD, F. P., DUDLEY, F. J., CHISHOLM, D. J., & FINDLAY, D. M. (1979). GLUCAGON METABOLISM IN NORMAL SUBJECTS AND IN CIRRHOTIC PATIENTS BEFORE AND AFTER PORTASYSTEMIC VENOUS SHUNT SURGERY. Clinical Endocrinology, 11(4), 413-424. DOI Scopus19 Europe PMC9
1979	Findlay, D. M., Omond, S., Alford, F. P., & Chisholm, D. J. (1979). Hyperglycemia and glucagon suppression: Possible importance of the vagus and enteric humoral factors. Journal of Clinical Endocrinology and Metabolism, 48(1), 13-16. DOI Scopus10 Europe PMC4
1978	Chisholm, D. J., Alford, F. P., Harewood, M. S., Findlay, D. M., & Gray, B. N. (1978). Nature and biologic activity of "extrapancreatic glucagon": Studies in pancreatectomized cats. Metabolism, 27(3), 261-273. DOI Scopus11 Europe PMC10
1977	PERRY‐KEENE, D. A., ALFORD., F. P., CHISHOLM., D. J., FINDLAY., D. M., LARKINS, R. G., & MARTIN, F. I. R. (1977). GLUCAGON AND DIABETES: I. THE FAILURE OF HYPERGLUCAGONAEMIA TO INFLUENCE THE RESPONSE OF ESTABLISHED DIABETIC KETOACIDOSIS TO THERAPY. Clinical Endocrinology, 6(6), 417-423. DOI Scopus4 Europe PMC1

Books

Year	Citation
2000	Haynes, D., Crotti, T., Loric, M., Atkins, G., Howie, D., Vernon-Roberts, B., & Findlay, D. (2000). Osteoclastogenic factors associated with periprosthetic osteolysis. USA.
2000	Crotti, T., Loric, M., Dalidjan, M., Atkins, G., Findlay, D., Howie, D., & Haynes, D. (2000). Expression of RANK, RANKL and OPG is associated with rheumatoid arthritic, periodontal and periprosthetic tissues. USA.

Book Chapters

Year	Citation
2020	Findlay, D. M. (2020). Osteoblasts in human skeletal diseases. In Encyclopedia of Bone Biology (pp. 499-512). DOI
2019	Martin, T. J., Moseley, J. M., Findlay, D. M., & Michelangeli, V. P. (2019). CALCITONIN PRODUCTION AND CALCITONIN RECEPTORS IN HUMAN CANCERS. In Hormones in Normal and Abnormal Human Tissues: Volume 1 (Vol. 1, pp. 429-457). De Gruyter. DOI Scopus5
2018	Findlay, D. (2018). Biology of bone and the interaction of bone with other organ systems. In P. Pivonka (Ed.), Multiscale Mechanobiologyof Bone Remodelingand Adaptation (Vol. 578, pp. 259-287). Switzerland: Springer. DOI Scopus3
2018	Anderson, P., Atkins, G., Morris, H., & Findlay, D. (2018). Vitamin D Activities in Osteocytes. In D. Feldman, J. W. Pike, R. Bouillon, E. Giovannucci, D. Goltzman, & M. Hewison (Eds.), Vitamin D: Fourth Edition (Vol. 1, 4th ed., pp. 319-327). London, United Kingdom: Academic Press. DOI Scopus1
2016	Findlay, D. M., Sexton, P. M., & Martin, T. J. (2016). Calcitonin. In J. L. Jameson, L. J. De Groot, & G. C. Weir (Eds.), Endocrinology: Adult and Pediatric (Vol. 1-2, 7th ed., pp. 1004-1017.e5). Philadelphia, PA; USA: Elsevier. DOI Scopus3
2016	Ostrovskaya, A., Findlay, D., Sexton, P., & Furness, S. (2016). Calcitonin. In The Curated Reference Collection in Neuroscience and Biobehavioral Psychology (pp. 220-230). Elsevier. DOI Scopus4
2015	Gulati, K., Kogawa, M., Maher, S., Atkins, G., Findlay, D., & Losic, D. (2015). Titania nanotubes for local drug delivery from implant surfaces. In D. Losic, & A. Santos (Eds.), Electrochemically Engineered Nanoporous Materials: Methods, Properties and Applications (Vol. 220, pp. 307-355). Switzerland: Springer. DOI Scopus41
2014	Davey, R., & Findlay, D. (2014). Physiological actions of calcitonin. In B. Nordin, H. Morris, & P. Anderson (Eds.), The Physiological Basis of Metabolic Bone Disease (pp. 187-200). Florida, United States: CRC Press.
2012	Findlay, D. (2012). Subchondral bone in osteoarthritis. In B. Rothschild (Ed.), Principles of Osteoarthritis - its Definition, Character, Derivation and Modality-Related Recognition (1 ed., pp. 139-154). Croatia: InTech. DOI
2011	Findlay, D., & Atkins, G. (2011). TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling. In D. Wallach, A. Kovalenko, & M. Feldmann (Eds.), Advances in TNF Family Research (Vol. 691, 1 ed., pp. 337-348). 233 Spring St New York NY 10013: Springer. DOI Scopus14 WoS12 Europe PMC10
2011	Atkins, G., Findlay, D., Anderson, P., & Morris, H. (2011). Target genes: Bone proteins. In D. Feldman, J. Pike, & J. Adams (Eds.), Vitamin D (Vol. 1, 3rd ed., pp. 411-424). Elsevier. DOI Scopus26
2011	Atkins, G. J., Findlay, D. M., Anderson, P. H., & Morris, H. A. (2011). Target Genes: Bone proteins. In Vitamin D: Two-Volume Set (Vol. 1-2, pp. 411-424). DOI
2010	Martin, T. J., Findlay, D. M., & Sexton, P. M. (2010). Calcitonin. In Endocrinology: Adult and Pediatric, Sixth Edition (Vol. 1, pp. 1074-1088). Elsevier. DOI Scopus1
2007	Findlay, D. (2007). Bone. In McGraw-Hill Encyclopaedia of Science and Technology, Vol. 3 (10th ed., pp. 206-208). New York: McGraw-Hill.
2006	Findlay, D., & Haynes, D. (2006). Bone resorption. In Wiley encyclopedia of biomedical engineering (pp. www1-www13). Hoboken, N.J: Wiley. DOI
2005	Findlay, D., Sexton, P., & Martin, T. (2005). Calcitonin. In L. De Groot, & J. Jameson (Eds.), Endocrinology (5th ed., pp. 1419-1433). Philadelphia, PA: Elsevier Saunders. DOI
2004	Atkins, G., Findlay, D., Anderson, P., & Morris, H. (2004). Target genes: bone proteins. In D. Feldman, J. Pike, & F. Glorieux (Eds.), Vitamin D, 2nd. ed (Vol. 1, 2nd ed., pp. 711-720). San Diego, California: Elsevier Academic Press. DOI Scopus3
2004	Atkins, G. J., Findlay, D. M., Anderson, P. H., & Morris, H. A. (2004). Target Genes: Bone Proteins. In Vitamin D, Second Edition (pp. 711-720). DOI
2003	Findlay, D., & Sexton, P. (2003). Calcitonin. In H. Henry, & A. W. Norman (Eds.), Encyclopedia of Hormones (pp. 220-230). San Diego: Academic Press. DOI
1998	Findlay, D. (1998). Calcitonin and its related proteins. In Calcitonin: Research and clinical applications (pp. 32-38). Life Science Publishing.
1997	Ng, K., Romas, E., Donnan, L., & Findlay, D. (1997). Bone Biology. In Metabolic Bone Disease (Vol. 11, pp. 1-22). WB Saunders Company. DOI Scopus38 Europe PMC15
1996	Martin, T., Findlay, D., & Moseley, J. (1996). Peptide Hormones Acting on Bone. In Osteoporosis (pp. 185-204). Academic Press.

Conference Papers

Year	Citation
2019	Kuliwaba, J. S., Lee, Y. -R., Muratovic, D., Gill, T. K., & Findlay, D. M. (2019). BIOCHEMICAL PROFILING OF BONE MARROW LESIONS IN KNEE OSTEOARTHRITIS PATIENTS: ALTERED MINERALIZATION OF THE SUBCHONDRAL BONE MATRIX. In OSTEOARTHRITIS AND CARTILAGE Vol. 27 (pp. S111). Toronto, CANADA: ELSEVIER SCI LTD. DOI WoS1
2017	Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2017). Hypoxia-activated pro-drug Evofosfamide exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. In CLINICAL & EXPERIMENTAL METASTASIS Vol. 34 (pp. 222-223). SPRINGER.
2017	Liapis, V., Zinonos, I., Labrinidis, A., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2017). Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. In CLINICAL & EXPERIMENTAL METASTASIS Vol. 34 (pp. 222). SPRINGER.
2016	Makar, S., Qin, J., Gulati, K., ElMekawy, A., Kaur, G., Lima-Marques, L., . . . Losic, D. (2016). 3D printed titanium implants with nano-engineered surface titania nanotubes for localized drug delivery. In Chemeca 2016 (pp. 1-12). online: Engineers Australia.
2015	Muratovic, D., Cicuttini, F. M., Wluka, A., Wang, Y., Findlay, D. M., Otto, S., . . . Kuliwaba, J. S. (2015). BONE MARROW LESIONS DETECTED BY DIFFERENT MAGNETIC RESONANCE SEQUENCES AS POTENTIAL BIOMARKERS FOR KNEE OSTEOARTHRITIS: COMPREHENSIVE TISSUE LEVEL ANALYSIS. In OSTEOARTHRITIS AND CARTILAGE Vol. 23 (pp. A303-A305). Seattle, WA: ELSEVIER SCI LTD. DOI WoS1
2014	Mokhtarzadeh, H., Aw, M., Khalid, K., Gulati, K., Atkins, G., Findlay, D., . . . Pivonka, P. (2014). Computational and experimental model of nano-engineered drug delivery system for trabecular bone. In E. Onate, X. Oliver, & A. Huerta (Eds.), 11th World Congress on Computational Mechanics, WCCM 2014, 5th European Conference on Computational Mechanics, ECCM 2014 and 6th European Conference on Computational Fluid Dynamics, ECFD 2014 (pp. 868-879). Barcelona, Spain: International Center for Numerical Methods in Engineering. Scopus1
2014	Ormsby, R., Findlay, D., Kogawa, M., Anderson, P., Morris, H., & Atkins, G. (2014). Analysis of vitamin D metabolism gene expression in human bone: evidence for autocrine control of bone remodelling. In D. Bikle, A. Norman, & J. Welsh (Eds.), The Journal of Steroid Biochemistry and Molecular Biology Vol. 144 (pp. 110-113). San Francisco, CA, USA: Elsevier. DOI Scopus24 WoS22 Europe PMC14
2013	Gulati, K., Atkins, G., Findlay, D., & Losic, D. (2013). Nano-engineered titanium for enhanced bone therapy. In Proceedings of the SPIE 2013 Optics & Photonics Conference Vol. 8812 (pp. 1-6). Online: SPIE-International Society for Optical Engineering. DOI Scopus26 WoS21
2012	Aw, M., Gulati, K., Atkins, G., Findlay, D., & Losic, D. (2012). Controlling drug release from titania nanotube arrays using polymer nanocarriers and biopolymer coating. In Proceedings of the 10th Asia-Pacific Microscopy Conference, APMC10, the International Conference on Nanoscience & Nanotechnology, ICONN2012 and the 22nd Australian Conference on Microscopy & Microanalysis, ACMM22 (pp. 655-1-655-2). Perth.
2011	Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011). SCLEROSTIN INDUCES OSTEOCYTE SUPPORT OF OSTEOCLAST FORMATION AND OSTEOCLAST ACTIVITY. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S550). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Atkins, G. J., Vincent, C., Wijenayaka, A. R., Welldon, K. J., Haynes, D. R., Zheng, T. S., . . . Findlay, D. M. (2011). THE EFFECTS OF TWEAK AND TNF ON HUMAN OSTEOBLASTS: MAPK DEPENDENT INDUCTION OF SCLEROSTIN EXPRESSION. In D. Wallach, A. Kovalenko, & M. Feldman (Eds.), ADVANCES IN TNF FAMILY RESEARCH Vol. 691 (pp. 688). San Lorenzo del Escorial, SPAIN: SPRINGER-VERLAG BERLIN.
2011	Welldon, K. J., Findlay, D. M., & Atkins, G. J. (2011). CALCIUM AS AN ANABOLIC STIMULUS OF OSTEOBLAST DIFFERENTIATION TO AN OSTEOCYTE-LIKE PHENOTYPE. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S611). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Findlay, D. M., Neale, S. D., Stamenkov, R., & Howie, D. W. (2011). THE NATURAL HISTORY OF PERIACETABULAR OSTEOLYTIC LESIONS. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S615). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Ito, N., Kogawa, M., Wijenayaka, A., Welldon, K., Khalid, K., Ormsby, R., . . . Findlay, D. M. (2011). PHOSPHATE 'SENSING' BY HUMAN BONE. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S585). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Khalid, K. A., Ormsby, R. T., Welldon, K. J., Lim, H. P., Syazwani, S., FatinNabilah, S., . . . Findlay, D. M. (2011). RESPONSE TO LOADING IN EX VIVO BOVINE BONE. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S570). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Kogawa, M., Findlay, D. M., Anderson, P. H., Morris, H. A., & Atkins, G. J. (2011). 25(OH)-VITAMIN D3 ACTS DIRECTLY ON OSTEOCLASTS TO REDUCE RESORPTION: WHAT IS THE MECHANISM?. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S586). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Evdokiou, A., Liapis, V., Hay, S., Keramidas, A., Maltezou, E., Christou, Y., . . . Odysseos, A. (2011). The vitamin E analogue Γ-tocotrienol blocks osteoclastogenesis and promotes osteogenesis: Evidence for combined anti-osteolytic and bone forming activity. In BONE Vol. 48 (pp. S106). Athens, GREECE: ELSEVIER SCIENCE INC. DOI
2009	Turner, A. G., Tjahyono, F. A., Chiu, W. S. M., Moore, A. J., Findlay, D. M., Morris, H. A., . . . Davey, R. A. (2009). The calcitonin receptor on osteoclasts plays a physiological role to protect against induced hypercalcaemia in mice. In BONE Vol. 44 (pp. S137-S138). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Lee, M., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression. In BONE Vol. 44 (pp. S54). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Welldon, K. J., Holding, C., Haynes, D. R., Howie, D. W., Findlay, D. M., & Atkins, G. J. (2009). Polyethylene particles activate pro-osteoclastogenic signalling pathways in human primary osteoblasts and osteocytes. In BONE Vol. 44 (pp. S127-S128). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Kogawa, M., Findlay, D. M., Anderson, P. H., Vincent, C., & Atkins, G. J. (2009). The metabolism of 25(OH)-vitamin D<sub>3</sub> by osteoclast precursors regulates the differentiation and function of osteoclasts. In BONE Vol. 44 (pp. S60-S61). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Wijenayaka, A. R., Vincent, C., Findlay, D. M., Welldon, K. J., Zheng, T. S., Haynes, D. R., . . . Atkins, G. J. (2009). The proinflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFa induce the mitogen activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. In BONE Vol. 44 (pp. S63). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI WoS1
2009	Atkins, G. J., Vincent, C., Wijenayaka, A. R., Welldon, K. J., & Findlay, D. M. (2009). TNF-related weak inducer of apoptosis (TWEAK) and sclerostin both signal via Erk-1/2 phosphorylation in human osteoblasts. In BONE Vol. 44 (pp. S56-S57). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2008	Anderson, P. H., Atkins, G. J., Sawyer, R. K., Findlay, D. M., O'Loughlin, P. D., & Morris, H. A. (2008). The Requirement of the Bone for Vitamin D for 1,25(OH)<sub>2</sub>D<sub>3</sub> Synthesis and Bone Mineralisation.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S429). Montreal, CANADA: WILEY-BLACKWELL. WoS1
2008	Atkins, G. J., Vincent, C., Wijenayaka, A. R., Welldon, K. J., Haynes, D. R., Zheng, T. S., . . . Findlay, D. M. (2008). The Proinflammatory Cytokine TWEAK Induces Sclerostin Expression in Human Immature Osteoblasts in a MAPK Dependent Fashion.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S385). Montreal, CANADA: AMER SOC BONE & MINERAL RES.
2008	Turner, A. G., Tjahyono, F., Chiu, W. S. M., Moore, A. J., Findlay, D. M., Morris, H. A., . . . Davey, R. A. (2008). The Calcitonin Receptor on Osteoclasts Plays a Physiological Role to Protect Against Hypercalcaemia in Mice. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S172). Montreal, CANADA: AMER SOC BONE & MINERAL RES.
2007	Atkins, G. J., Vincent, C., Welldon, K. J., Haynes, D. R., Holding, C., Zheng, T. S., . . . Findlay, D. M. (2007). TWEAK is a regulator of human osteoblast function. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 22 (pp. S138). Honolulu, HI: AMER SOC BONE & MINERAL RES.
2007	Ng, D., Tian, W., Withayachumnankul, W., Findlay, D., Ferguson, B., & Abbott, D. (2007). Classification of osteosarcoma T-ray responses using adaptive and rational wavelets for feature extraction. In Derek Abbott (Ed.), Proceedings of SPIE Microelectronics, MEMS, and Nanotechology Vol. 6802 (pp. 1-13). CDROM: SPIE. DOI Scopus3
2006	Withayachumnankul, W., Ferguson, B., Rainsford, T., Findlay, D., Mickan, S., & Abbott, D. (2006). T-ray relevant frequencies for osteosarcoma classification. In J. M. Bell, & V. K. Varadan (Eds.), Proceedings of Microelectronics, MEMS, and Nanotechnology 2005 Vol. 6038 (pp. 60381H-1-60381H-15). http://www.spie.org/conferences/programs/05/au/: SPIE. DOI Scopus6 WoS3
2006	Welldon, K., Atkins, G., Vincent, C., & Findlay, D. (2006). Vitamin K analogues promote the differentiation of human osteoblasts.. In Journal of Bone Mineral Research Vol. 21 (pp. SA-204.). Philadelphia, Pennsylvania: American Society for Bone and Mineral Research.
2006	Atkins, G. J., Welldon, K. J., Vincent, C., & Findlay, D. M. (2006). Vitamin K analogues promote the differentiation of primary human osteoblasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 21 (pp. S155). Philadelphia, PA: AMER SOC BONE & MINERAL RES.
2006	Zarrinkalam, M. R., Nattrass, G., Beard, H., Atkins, G. J., Findlay, D. M., & Moore, R. J. (2006). Mechanisms of trabecular bone loss in an ovine model of osteoporosis. In OSTEOPOROSIS INTERNATIONAL Vol. 17 (pp. S324). Washington, DC: SPRINGER LONDON LTD.
2006	Findlay, D. M. (2006). Bone physiology and pathology: Complementary insights from non-invasive imaging to tissues to molecules. In Journal of Histotechnology Vol. 29 (pp. 201-202). Informa UK Limited. DOI
2006	Davey, R. A., Chiu, M. W. S., Moore, A. J., McManus, J. F., Glatt, V., Ma, C., . . . Zajac, J. D. (2006). Trabecular bone volume in young female mice is dependent on calcitonin receptor expression in osteoclasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 21 (pp. S196). Philadelphia, PA: AMER SOC BONE & MINERAL RES.
2005	Evdokiou, A., Minh, L. T., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., . . . Findlay, D. M. (2005). Apo2L/TRAIL is a potent anticancer agent that prevents breast cancer-induced bone destruction in a mouse model. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. P35). Bethesda, MD: AMER SOC BONE & MINERAL RES.
2005	Davey, R. A., McManus, J. F., Moore, A. J., Chiu, M. W. S., Axell, A. M., Notini, A. J., . . . Zajac, J. D. (2005). Global knock-down of the calcitonin receptor (CTR) results in decreased trabecular bone volume in young female mice.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. S41). Nashville, TN: AMER SOC BONE & MINERAL RES.
2005	Bhattacharyya, S., Siegel, E., Findlay, D. M., Fazzalari, N. L., Chehade, M., Neale, S., . . . Suva, L. J. (2005). Biomarker discovery in osteoarthritis.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. S225). Nashville, TN: AMER SOC BONE & MINERAL RES.
2005	Bouralexis, S., Findlay, D. M., Atkins, G. J., Hay, S., & Evdokiou, A. (2005). Chemotherapy sensitises osteogenic sarcoma cells but not normal cells to trail-induced apoptosis. In CANCER TREATMENT REVIEWS Vol. 31 (pp. S33-S34). Davos, SWITZERLAND: W B SAUNDERS CO LTD.
2005	Findlay, D. M., Howie, D. W., McGee, M. A., Stamenkov, R., Neale, S., Taylor, J. D., . . . Kourlis, G. (2005). Polyethylene wear influences progression of pelvic peri-prosthetic osteolysis. In BONE Vol. 36 (pp. S241-S242). Geneva, SWITZERLAND: ELSEVIER SCIENCE INC.
2005	Atkins, G. J., Kostakis, P., Vincent, C., Farrugia, A. N., Findlay, D. M., Evdokiou, A., & Zannettino, A. C. W. (2005). RANK expression in normal and malignant haemopoietic cells: A monoclonal antibody study.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. S146). Nashville, TN: AMER SOC BONE & MINERAL RES.
2005	Evdokiou, A., Findlay, D. M., Minh, T. L., Labrinidis, A., Hay, S., Liapis, V., . . . Welldon, K. (2005). Apo2L/TRAIL is a potent anti-cancer agent that prevents breast cancer-induced bone destruction in a mouse model. In BONE Vol. 36 (pp. S144). Geneva, SWITZERLAND: ELSEVIER SCIENCE INC.
2005	Dharmapatni, A. A. S. S. K., Findlay, D. M., Smith, M. D., Evdokiou, A., Chen, P., Screaton, G. R., . . . Haynes, D. R. (2005). Regulating the sensitivity of synovial fibroblasts to trail-induced apoptosis. In ANNALS OF THE RHEUMATIC DISEASES Vol. 64 (pp. 154). Vienna, AUSTRIA: BMJ PUBLISHING GROUP.
2005	Kostakis, P., Atkins, G., Vincent, C., Farrugia, A., Findlay, D., Evdokiou, A., & Zannettino, A. (2005). RANK expression in normal and malignant cells: a monoclonal antibody study. In Journal of Bone and Mineral Research Vol. 20 (pp. SA-259.). Nashville, Tennessee: American Society for Bone and Mineral Research.
2004	Atkins, G., Anderson, P., Welldon, K., Zannettino, A., Morris, H., & Findlay, D. (2004). Vitamin D metabolism in human osteoblasts. In Journal of Bone and Mineral Research Vol. 19 (pp. SA-587). Seattle, Washington: American Society for Bone and Mineral Research.
2004	Ferguson, B., Liu, H., Hay, S., Findlay, D., Zhang, X., & Abbott, D. (2004). In vitro osteosarcoma biosensing using THz time domain spectroscopy. In L. Faraone, & V. K. Vardan (Eds.), Proceedings of SPIE on CD-Rom Vol. 5275 (pp. 304-316). CD-ROM: SPIE. DOI Scopus14 WoS10
2004	Labrinidis, A., Nguyen, O. K., Bouralexis, S., Hay, S., Findlay, D. M., & Evdokiou, A. (2004). Inhibitors of the mevalonate pathway sensitize osteosarcoma cells to Apo21/trail-induced cell death. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 19 (pp. 1572). San Antonio, TX: AMER SOC BONE & MINERAL RES.
2004	Atkins, G. J., Anderson, P. H., Welldon, K., Zannettino, A. C. W., Morris, H. A., & Findlay, D. M. (2004). Vitamin D metabolism in human osteoblasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 19 (pp. S204). Seattle, WA: AMER SOC BONE & MINERAL RES.
2004	Lucas, H., Zreiqat, H., Gross, K. A., Holding, C., Findlay, D. M., Wallwork, M., & Haynes, D. R. (2004). Osteoclast resorption of hydroxyapatite bone substitute materials in vitro. In Transactions - 7th World Biomaterials Congress (pp. 1309).
2003	Atkins, G. J., Anderson, P. H., Morris, H. A., Zannettino, A. C. W., Kostakis, P., & Findlay, D. M. (2003). The expression of 25-hydroxyvitamin D 24-hydroxylase and 25-hydroxyvitamin D 1 alpha-hydroxylase in human osteoblasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 18 (pp. S409). MINNEAPOLIS, MINNESOTA: AMER SOC BONE & MINERAL RES.
2003	Dassios, H., Findlay, D. M., Kuliwaba, J. S., Atkins, G. J., & Fazzalari, N. L. (2003). Enhanced gene expression of osteoclastogenic factors in human osteoporotic trabecular bone. In BONE Vol. 32 (pp. S149). OSAKA, JAPAN: ELSEVIER SCIENCE INC.
2003	Pan, B. Q., To, L. B., Farrugia, A. N., Kostakis, P., Atkins, G. J., Findlay, D. M., & Zannettino, A. C. W. (2003). Multiple myeloma-derived pro-inflammatory cytokines enhance osteoclastogenesis by increasing the number of RANKL-expressing STRO-1 positive osteoprogenitor cells.. In BLOOD Vol. 102 (pp. 370B). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
2003	Kostakis, P., Atkins, G., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). The relationship between RANKL expression and osteoblast differentiation in human osteoblasts. In 30th European Symposium on Calcified Tissues, 8-12 May 2003 Vol. Italy (pp. 314-468). Rome, Italy: Springer Science and Business Media LLC. DOI
2002	Atkins, G., Zannettino, A., Kostakis, P., Pan, B., Farrugia, A., Evdokiou, A., & Findlay, D. (2002). Evidence for the maturation-dependent expression of an osteoclastogenic phenotype in human osteoblasts.. In Journal of Bone and Mineral Research Vol. 17 (pp. S446.). San Antonio, Texas: American Society for Bone and Mineral Research.
2002	Atkins, G., Pan, B., Findlay, D., To, L., Evdokiou, A., Labrinidis, A., . . . Zannettino, A. (2002). Zoledronate is anabolic for human osteoblast-like cells. In Journal of Bone and Mineral Research Vol. 17 (pp. S442.). San Antonio, Texas: American Society for Bone and Mineral Research.
2001	Atkins, G., Kuliwaba, J., Findlay, D., Forwood, M., & Fazzalari, N. (2001). Differential Gene Expression in the Human Bone Microenvironment of the Hip; Comparison Between Control and Osteoarthritis.. In Journal of Bone and Joint Surgery (Br.) Vol. 84-B (pp. 235). Adelaide, South Australia: The British Editorial Society of Bone and Joint Surgery.
1999	Crotti, T. N., Potter, A. E., Atkins, G. J., Findlay, D. M., Howie, D. W., & Haynes, D. R. (1999). Osteoclast differentiation and development is regulated by mediators released in response to prosthetic particles. In H. Stein, S. I. Suk, P. C. Leung, K. G. Thorngren, & W. Akeson (Eds.), SIROT 99 (pp. 542-546). SYDNEY, AUSTRALIA: FREUND PUBL HOUSE LTD.
1999	Kuliwaba, J. S., Findlay, D. M., Atkins, G. J., Forwood, M. R., & Fazzalari, N. L. (1999). Gene expression in osteoarthritic cancellous bone is consistent with osteoarthritis being a disease of the skeleton. In H. Stein, S. I. Suk, P. C. Leung, K. G. Thorngren, & W. Akeson (Eds.), SIROT 99 (pp. 437-441). SYDNEY, AUSTRALIA: FREUND PUBL HOUSE LTD.
1999	Atkins, G. J., Loric, M., Crotti, T. N., Haynes, D. R., & Findlay, D. M. (1999). Osteoclast differentiation factors are expressed by both stromal and haematopoietic cells in human osteoclast formation. In H. Stein, S. I. Suk, P. C. Leung, K. G. Thorngren, & W. Akeson (Eds.), SIROT 99 (pp. 547-551). SYDNEY, AUSTRALIA: FREUND PUBL HOUSE LTD.
1995	Martin, T. J., Findlay, D. M., Houssami, S., Ikegame, M., Rakopoulos, M., Moseley, J. M., & Sexton, P. M. (1995). Heterogeneity of the calcitonin receptor: Functional aspects in osteoclasts and other sites. In Journal of Nutrition Vol. 125 (pp. 2009S-2014S). United States: Elsevier BV. DOI Scopus10 Europe PMC4
1990	Ng, K. W., Manji, S. S., Young, M. F., & Findlay, D. M. (1990). Interaction of retinoic acid and other factors on transcriptional activity of pre-osteoblasts. In Calcium regulation and bone metabolism. Basic and clinical aspects: proceedings of the 10th International Conference on calcium regulating hormones and bone metabolism. ICS886 (pp. 311-316).
1990	Sexton, P. M., D'Santos, C. S., Mendelsohn, F. A. O., Schneider, H. G., Findlay, D. M., Kemp, B. E., & Moseley, J. M. (1990). Characterization of sheepbrain calcitonin receptors. In Calcium regulation and bone metabolism. Basic and clinical aspects: proceedings of the 10th International Conference on calcium regulating hormones and bone metabolism. ICS886 (pp. 57-63). Scopus3
1977	Caruso, G., Findlay, D. M., Alford, F. P., Dudley, F., & Chisholm, D. J. (1977). THE MULTIPLE FORMS OF CIRCULATING “GLUCAGON”. In Australian and New Zealand Journal of Medicine Vol. 7 (pp. 686). Wiley. DOI

Conference Items

Year	Citation
2021	Muratovic, D., Findlay, D. M., Masri, H. H., Stapledon, C. J., Lee, Y., Cao, X., . . . Kuliwaba, J. S. (2021). ELEVATED LEVELS OF ACTIVE TRANSFORMING GROWTH FACTOR beta 1 IN THE SUBCHONDRAL BONE RELATE SPATIALLY TO IMPAIRED BONE QUALITY AND CARTILAGE LOSS IN HUMAN KNEE OSTEOARTHRITIS. Poster session presented at the meeting of OSTEOARTHRITIS AND CARTILAGE. ELSEVIER SCI LTD. DOI
2017	Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2017). Anticancer efficacy of the hypoxia-activated pro-drug evofosfamide in prcelinIcal osteosarcoma murine models. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. SPANDIDOS PUBL LTD.
2017	Liapis, V., Zinonos, I., Labrinidis, A., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2017). The hypoxia activated pro-drug evofosfamide exhibits tumour suppressive activity and synergy with chemotherapy against primary and metastatic breast cancers. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. SPANDIDOS PUBL LTD.
2014	Kuliwaba, J. S., Lee, Y. -R., Naas, S., Muratovic, D., Humphries, J. M., & Findlay, D. M. (2014). THE PATHOPHYSIOLOGY OF SUBCHONDRAL CANCELLOUS BONE IN POSTMENOPAUSAL KNEE OSTEOARTHRITIS: DIFFUSE MICRODAMAGE ACCUMULATION, OSTEOCYTE CELL DEFICIENCY AND BONE MARROW HYPERVASCULARITY. Poster session presented at the meeting of OSTEOARTHRITIS AND CARTILAGE. Paris, FRANCE: ELSEVIER SCI LTD. DOI
2009	Labrinidis, A., Hay, S., Liapis, V., Findlay, D. M., & Evdokiou, A. (2009). Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Poster session presented at the meeting of CLINICAL & EXPERIMENTAL METASTASIS. SPRINGER. WoS2
2003	Anderson, P., Atkins, G., Morris, H., Kostakis, P., Findlay, D., & Zannettino, A. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts.. Poster session presented at the meeting of Calcified Tissue International. Rome, Italy: Springer.
2003	Atkins, G., Anderson, P., Morris, H., Zannettino, A., Kostakis, P., & Findlay, D. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts. Poster session presented at the meeting of Journal of Bone Mineral Research. Minnesota, USA.

Datasets

Year	Citation
2006	Rinkalam, M., Atkins, G., Natrass, G., Beard, H., & Findlay, D. (2006). EF121766 Ovis aries osteoprotegerin mRNA, partial cds.
2006	Zarrinkalam, M., Atkins, G., Natrass, G., Beard, H., & Findlay, D. (2006). EF121765 Ovis aries nuclear factor kappa B ligand mRNA, partial cds.
2004	Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_001004419 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 2, mRNA.
2004	Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_013269 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 1, mRNA.

Software

Year Citation

2020 Solomon, L. B., Atkins, G., Freeman, B., Howie, D., Findlay, D., Smitham, P., . . . Jones, C. (2020). COTR publications [website]. University of Adelaide: Dan McCafferty.

Year	Citation
2020	Solomon, L. B., Atkins, G., Freeman, B., Howie, D., Findlay, D., Smitham, P., . . . Jones, C. (2020). COTR publications [website]. University of Adelaide: Dan McCafferty.

Preprint

Year	Citation
2021	Hofstaetter, J., Atkins, G., Kogawa, M., Blouin, S., Misof, B., Roschger, P., . . . Ito, N. (2021). A case of autosomal dominant osteopetrosis type II with a severe bone phenotype but no amino acid converting mutation in the <i>CLCN7</i> gene. DOI

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2016 - 2019	Co-Supervisor	The Role of the Osteocyte in Periprosthetic Osteolysis	Doctor of Philosophy	Doctorate	Full Time	Ms Renee Ormsby
2015 - 2019	Principal Supervisor	The establishment of an automated, electronic data-collection system for the purpose of qualifying, evaluating and improving post-operative surgical outcomes and evidence-based surgery	Doctor of Philosophy	Doctorate	Part Time	Dr James Marcus McLean
2014 - 2017	Principal Supervisor	Evaluation of Low Grade Bacterial Infection of the Intervertebral Disc	Master of Philosophy (Surgery)	Master	Part Time	Thomas James Fisher
2013 - 2018	Co-Supervisor	Bone Marrow Lesions in Progression of Knee Osteoarthritis	Doctor of Philosophy	Doctorate	Full Time	Dr Dzenita Muratovic
2012 - 2015	Co-Supervisor	Nano-Engineered Titanium Implants for Complex Bone Therapies	Doctor of Philosophy	Doctorate	Full Time	Mr Karan Gulati
2011 - 2012	Co-Supervisor	The Effect of Bone Anabolic Stimuli on Human Osteoblast to Osteocyte Transition	Master of Philosophy (Medical Science)	Master	Full Time	Ms Katie Welldon
2010 - 2014	Co-Supervisor	The regulation of the sclerostin gene and the catabolic effects of sclerostin protein on bone	Doctor of Philosophy	Doctorate	Full Time	Dr Asiri Wijenayaka
2009 - 2019	Co-Supervisor	Ex Vivo Bone Culture: A Novel Method for Investigating Mechanical Loading Response and Osteocytes in Situ In Trabecular Bone	Doctor of Philosophy	Doctorate	Full Time	Dr Kamarul Ariffin Khalid
2007 - 2009	Principal Supervisor	An Anatomical Basis for the Management of Complex Wrist Injuries	Master of Surgery	Master	Part Time	Dr James Marcus McLean
2007 - 2012	Co-Supervisor	The Effectsof the Histone Deacetylase Inhibitor LBH589 on Breast Cancer in Bone and on Physiological Bone Remodelling	Doctor of Philosophy	Doctorate	Full Time	Ms Michelle Lee
2003 - 2007	Co-Supervisor	Apo 2L/TRAIL in Breast Cancer Bone Metastasis: in vitro and in vivo Studies into Molecular Mechanisms of Action and Resistance	Doctor of Philosophy	Doctorate	Full Time	Mr Le Thai
2003 - 2007	Co-Supervisor	Trail Mediated Apoptosis in Arthritis	Doctor of Philosophy	Doctorate	Full Time	Ms Anak Dharmapatni
2002 - 2009	Co-Supervisor	Computed Tomography Technique for the Measurement of Bone Defects Adjacent to Uncemented Acetabular Components of Total Hip Replacement	Master of Surgery	Master	Part Time	Dr Roumen Botev Stamenkov
2000 - 2003	Principal Supervisor	Molecular Mechanisms of Apo2L/TRAIL Induced Apoptosis In Normal and Malignant Cells	Doctor of Philosophy	Doctorate	Full Time	Mr Stelios Bouralexis
1999 - 2003	Co-Supervisor	GENE EXPRESSION, BONE REMODELLING, AND MICRODAMAGE IN THE HUMAN PROXIMAL FEMUR: A MOLECULAR HISTOMORPHOMETRIC ANALYSIS OF OSTEOARTHRITIC BONE	Doctor of Philosophy	Doctorate	Full Time	Dr Julia Kuliwaba
1999 - 2002	Co-Supervisor	MEDIATORS OF LOCALISED PATHOLOGICAL BONE LOSS	Doctor of Philosophy	Doctorate	Full Time	APrf Tania Crotti

Email: david.findlay@adelaide.edu.au

David Findlay

Appointments

Education

Postgraduate Training

Research Interests

Journals

Books

Book Chapters

Conference Papers

Conference Items

Datasets

Software

Preprint

Past Higher Degree by Research Supervision (University of Adelaide)

Connect With Me

External Profiles

Other Links